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1.1 Summary 
 
Angiogenesis is a very complex biological process that drives the formation of new blood 
vessels starting from pre-existing one. In adulthood, it occurs both in physiological and 
pathological processes. Pathological angiogenesis is involved in several diseases, 
characterized from an excessive process (cancer), or an insufficient vessels support 
(ischemia) and it was proposed as the ideal target of several disorders. The best studied 
and characterized family of factors involved in angiogenesis is the VEGF (Vascular 
Endothelial Growth Factor) family. It comprises seven glycosilated dimeric secreted 
proteins that bind three tyrosine kinase receptors. In angiogenesis system, VEGF-A and 
placental growth factor (PlGF) have a crucial role. VEGF-A, binds VEGFR-1 (Flt-1) and 
VEGFR-2 (KDR/Flk-1) receptors while PlGF binds exclusively Flt-1 with high affinity than 
VEGF-A. In vivo studies have demonstrated that while VEGF-A is involved both in 
physiological and pathological angiogenesis, the role of PlGF and Flt-1 is restricted to 
pathological processes. Recent data demonstrated that PlGF and Flt-1 are not only 
involved in pathological angiogenesis but also in inflammation disorders and metastasis 
formation.  
The aim of this study has been the identification of new small molecule able to prevent the 
binding of Flt-1 to its ligands, using the biotechnological approach of the screening of 
combinatorial peptide libraries. In general small molecules are more attracting for industrial 
production, with regard to recombinant protein and monoclonal antibodies, due to low cost 
and more easy process of production. The screening of a tetrameric tripeptide library 
made of 29 non natural aminoacids plus L-Glycine, has allowed the identification of the 
Gly-Lys(Lys2)-[4-23-5]4 peptide, named 4-23-5. Selected peptide is able to bind specifically 
Flt-1 receptor inhibiting the interaction with its ligands PlGF and VEGF showing an activity 
on micromolar range (IC50 of about 10 M). The activity of selected peptide depends both 
on aminoacidic sequence and on tetrameric structure as demonstrated respectively by 
assays performed with Ala-scanning peptides and structural analogues of tetrameric 4-23-
5. Selected peptide has an elevated resistance to proteases since it is stable until 24 hours 
as expected using non natural aminoacids. On cell 4-23-5 peptide is able to prevent PlGF-
induced Flt-1 phosphorilation indicating that it is able to prevent the first molecular event 
that actives angiogenesis in response to Flt-1. Moreover, 4-23-5 blocking peptide is able to 
inhibit both the formation of a capillary-like network induced by both PlGF and VEGF-A 
and the VEGF-induced angiogenesis on chicken embryo chorioallantoic membrane, 
showing that the inhibition of phosphorilation of Flt-1 alone is sufficient to inhibit 
angiogenesis both in vitro and in vivo. In addition, selected peptide is able to induce the 
vascularization of cornea in vivo confirming its ability to bind selectively Flt-1 without 
preventing VEGF-A/Flk-1 interaction that lead corneal vascularization.  
On the base of these results, selected peptide represents a new specific anti-Flt-1 peptide 
that it can be used for molecular therapy approach of those pathologies in which 
angiogenesis represents crucial events, for the treatment of inflammation disorders and to 
prevent cancer metastases. This peptide represents a new molecular scaffold which can 
be further modified to generate new peptide variants with increased affinity for its specific 
target. 
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1.2 Sommario 
 
Il sistema vascolare è il primo apparato formato durante lo sviluppo embrionale, esso 
infatti provvede a rifornire i tessuti di sostanze nutrienti e di ossigeno e allo stesso tempo 
allontana da questi i metaboliti di scarto. Il sistema vascolare viene formato attraverso due 
processi  distinti:  la  vasculogenesi  e  l’angiogenesi.  La  vasculogenesi è il processo di 
formazione di nuovi vasi sanguinei a partire dagli emangioblasti, precursori di origine 
staminale comuni sia alle cellule endoteliali che a quelle ematopoietiche. Il plesso 
vascolare primitivo formatosi in seguito alla vasculogenesi è ancora fragile e prono a 
rotture e necessita del processo angiogenico per ricevere stabilizzazione. L’angiogenesi è 
il processo di formazione di nuovi vasi sanguinei a partire dai vasi pre-esistenti. Tale 
processo avviene sia durante lo sviluppo embrionale, dove provvede a riorganizzare e 
stabilizzare  la  rete  vasale  primitiva,  sia  nell’adulto  dove  viene  distinta  in  angiogenesi 
fisiologica  e  patologica.  In  particolare  l’angiogenesi  patologica  interviene  in  numerose 
patologie  caratterizzate  sia  da  un’eccessiva angiogenesi, come nel cancro e nella 
retinopatia diabetica, che da un insufficiente processo angiogenico come nelle ischemie. 
La  terapia  angiogenica  nasce  con  l’intento  di  curare  quelle  patologie  caratterizzate  da 
un’eccessiva  angiogenesi  come  il  cancro, ma nel tempo è stata estesa a tutte quelle 
patologie causate o caratterizzate da un’angiogenesi alterata. 
I meccanismi molecolari  che  governano  l’angiogenesi  sono molteplici  e  negli  anni  sono 
state individuate diverse famiglie di fattori molecolari coinvolti sia nell’induzione che nella 
regolazione di tale processo. Tra queste, la famiglia di fattori di crescita più studiata e 
meglio caratterizzata è la famiglia dei fattori vascolari-endoteliali chiamata VEGF (Vascular 
Endothelial Growth Factor). Tale famiglia comprende sette proteine secrete denominate 
come: VEGF-A, -B e PlGF coinvolte nell’angiogenesi, VEGF-C e –D che prendono parte 
nella linfoangiogenesi, VEGF-E isolata di recente nel Pox virus e la cui funzione non è 
ancora stata chiarita, e infine VEGF-F recentemente isolato nel veleno della vipera. Tutti i 
membri di tale famiglia sono attivi come dimeri glicosilati che, a livello strutturale sono 
caratterizzati da un motivo ricco in residui di cisteina altamente conservato, noto come 
Cysteine knot. Essi legano i recettori di tipo tirosina-chinasi chiamati VEGFR-1 (conosciuto 
come Flt-1 (fms-like tyrosine kinase)), VEGFR-2 (chiamato KDR (kinase domain receptor) 
nell’uomo e Flk-1 (Fetal liver kinase) nel topo) e VEGFR-3 (anche conosciuto come Flt-4), 
in particolare il recettore Flt-1 esiste anche in forma solubile generata attraverso un 
processo di splicing alternativo. Inoltre VEGF-A e PlGF legano anche i co-recettori 
Neuropilina-1 e -2, ma il ruolo di tali interazioni è ancora oggi oggetto di studi atti a 
chiarirne  il  significato biologico. Per  quanto  riguarda  i  fattori  coinvolti  nell’angiogenesi,  è 
stato dimostrato che mentre VEGF-A lega entrambi i recettori Flt-1 e KDR/Flk-1 mostrando 
maggiore affinità per il primo, VEGF-B e PlGF legano esclusivamente Flt-1, e in particolare 
PlGF mostra affinità maggiore rispetto a VEGF-A e -B. Il legame dei fattori solubili ai 
recettori causa la dimerizzazione e la fosforilazione dei recettori, eventi molecolari che 
danno inizio alla cascata di trasduzione del segnale. 
Studi genetici hanno dimostrato che VEGF-B  è  coinvolto  nell’angiogenesi  specifica  del 
muscolo cardiaco, mentre VEGF-A ha un ruolo cruciale nell’induzione dell’angiogenesi in 
tutti i tessuti. In particolare, VEGF-A  interviene  sia  nell’angiogenesi  patologica che 
fisiologica, nonché nello sviluppo embrionale. Infatti la delezione di un singolo allele del 
gene vegf-a provoca letalità embrionale, indicando che per il corretto sviluppo embrionale 
è importante non solo la sua presenza ma anche la sua concentrazione. Al contrario, il 
ruolo di PlGF e del recettore Flt-1 è ristretto alla sola angiogenesi patologica. I topi Plgf-/- 
pur  essendo  vitali  e  fertili,  presentano  un’angiogenesi  patologica  alterata,  infatti  essi 
sviluppano tumori di dimensioni minori e meno vascolarizzati e hanno una minore capacità 
di recupero in seguito ad un evento ischemico. Un fenotipo simile è stato osservato nei 
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topo Flt-TK-/-, nei quali è stato eliminato il dominio tirosina-chinasi del recettore, mentre la 
delezione del gene Flt-1, così come la delezione del gene Flk-1, provoca letalità 
embrionale in seguito a difetti nella migrazione e stabilizzazione del plesso vasale 
primitivo. Ulteriori dati ottenuti inibendo PlGF o Flt-1 con anticorpi monoclonali, dimostrano 
che tali fattori sono coinvolti non solo nell’induzione dell’angiogenesi patologica, ma anche 
nel richiamo di cellule muscolari lisce che hanno il ruolo di stabilizzare i neo-vasi, e nel 
richiamo dei monociti/macrofagi che intervengono nelle patologie infiammatorie. Inoltre, 
per il recettore Flt-1 è stato descritto un ruolo singolare nel processo di formazioni delle 
metastasi: in vivo, in sistemi modello di crescita tumorale Flt-1 è espresso dai precursori 
ematopoietici di origine staminale che promuovono la formazione di aggregati cellulari che 
colonizzano i siti dove si avrà la formazione delle metastasi, tali aggregati prendono il 
nome  di  ‘nicchie  pre-metastatiche’.  L’utilizzo  di  un  anticorpo  anti-Flt-1 è capace di 
prevenire la formazione delle nicchie pre-metastatiche inibendo la formazione di 
metastasi. 
Inizialmente la terapia angiogenica si è concentrata su VEGF-A e sul recettore KDR/Flk-1, 
in  quanto  la  loro  funzione  è  cruciale  per  l’attivazione  delle  cellule  endoteliali  per  la 
formazione di nuovi vasi. Attualmente è in uso in terapia un anticorpo monoclonale anti 
VEGF-A (Avastin) per la cura del cancro. I risultati ottenuti con tale anticorpo mostrano 
chiaramente la validità del principio della terapia angiogenica, infatti inibendo l’angiogensi 
è possibile osservare un rallentamento della patologia, tuttavia i pazienti trattati hanno 
manifestato una serie di effetti collaterali quali trombosi e ipertensione, dovuti al fatto che 
VEGF-A è un fattore che induce la permeabilizzazione dei vasi e che riveste un ruolo 
importante anche nei processi fisiologici. 
In tale contesto si inserisce il seguente progetto di ricerca, volto ad identificare nuove 
piccole molecole capaci di inibire in maniera specifica l’angiogenesi patologica, che risulta 
essere più specificamente attivata dal recettore Flt-1 e dai suoi ligandi. A questo scopo è 
stato utilizzato come approccio la selezione di molecole bio-attive da collezioni peptidiche 
combinatoriali. Nell’ultimo decennio l’utilizzo in terapia di proteine ricombinanti e anticorpi 
monoclonali ha trovato largo impiego, tuttavia questo ha ancora degli svantaggi legati sia 
agli elevati costi di produzione che alle limitate modalità di somministrazione. In risposta a 
tali problemi, negli ultimi anni le biotecnologie si sono focalizzate anche sulle molecole a 
basso peso molecolare in quanto queste mostrano numerosi vantaggi primo fra tutti i bassi 
costi di produzione. In particolare è stata ampiamente studiata la realizzazione di collezioni 
di tali molecole, in modo da ottenere un numero elevato di molecole da analizzare, e sulle 
tecniche sperimentali per la loro analisi che permettano di selezionare molecole bio-attive. 
Nel  seguente  lavoro  è  stata  eseguita  la  sintesi  e  l’analisi  di  una  collezione  di  tri-peptidi 
tetramerici. La collezione è stata sintetizzata a partire da 29 aminoacidi non naturali più la 
L-Glicina in modo da ottenere peptidi stabili alle proteasi, mentre la struttura tetramerica è 
stata realizzata grazie ad un core di tre residui di lisina. Tale struttura è stata adottata per 
aumentare l’attività dei peptidi  in quanto questa contiene la stessa sequenza tri-peptidica 
ripetuta 4 volte. Il processo di selezione è stato eseguito mediante un saggio di 
competizione basato sulla metodica ELISA (Enzyme-linked immuno sorbent assay). Tale 
saggio consente di selezionare molecole capaci di  inibire  l’attività di Flt-1 di legare i suoi 
ligandi: una forma ricombinante del recettore Flt-1 viene fatta adsorbire su un supporto 
solido, quindi si aggiunge una forma ricombinante della proteina PlGF, in presenza di un 
eccesso molare noto di molecole da analizzare. L’interazione tra PlGF e il recettore viene 
rilevata utilizzando un anticorpo anti-PlGF biotinilato. Il saggio è eseguito con la proteina 
PlGF in quanto questa presenta maggiore affinità per Flt-1 rispetto a VEGF-A e quindi 
aumenta la sensibilità del saggio. Allo scopo di verificare la specificità dei peptidi ottenuti, 
è  stata  valutata  anche  la  capacità  di  questi  di  inibire  l’interazione  di  Flt-1 con VEGF-A. 
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Inoltre tutte le  molecole selezionate con il sistema murino sono state testate anche sul 
sistema umano per confermare la loro applicabilità in terapia. 
La deconvoluzione di una collezione peptidica è un processo basato su un saggio 
funzionale, che consente di stabilire per ogni posizione aminoacidica del peptide, il residuo 
che presenta maggiore attività. Il processo di deconvoluzione della collezione tetramerica 
ha identificato un peptide con sequenza Gly-Lys(Lys2)-[4-23-5]4 (in seguito indicato solo 
con 4-23-5), tale peptide è capace di inibire l’interazione tra il recettore Flt-1 e i suoi ligandi 
PlGF e VEGF-A mostrando attività su scala micro molare (IC50 10 M).  
Allo scopo di stabilire le basi molecolari che guidano l’attività del peptide selezionato, sono 
stati eseguiti dei saggi ELISA con il peptide immobilizzato per determinare con quale 
fattore questo fosse in grado di interagire. Tali saggi hanno dimostrato che il peptide 
selezionato è capace di interagire esclusivamente con il recettore Flt-1 mentre non 
interagisce con i fattori solubili PlGF e VEGF-A e con il recettore KDR/Flk-1.  
Per stabilire la relazione tra sequenza aminoacidica individuata ed attività inibitoria è stata 
eseguita una procedura nota come Alanine-scanning. Tale procedura consiste nel 
sintetizzare per ogni posizione aminoacidica, un peptide che presenta tale posizione 
sostituita con l’aminoacido L-Alanina. L’analisi di tali varianti peptidiche eseguita mediante 
saggio  ELISA  rivela  l’eventuale  presenza  di  residui  cruciali  per  l’attività  del  peptide.  Gli 
esperimenti di Alanine-scanning hanno dimostrato che l’attività inibitoria osservata dipende 
strettamente dalla sequenza aminoacidica, infatti tutti i residui aminoacidici sono essenziali 
per l’attività. 
Altro  parametro  che  determina  l’attività  di  un  peptide  è  la  sua  struttura. Allo scopo di 
stabilire il contributo della struttura tetramerica all’attività inibitoria mostrata dal peptide 4-
23-5, sono stati sintetizzati e analizzati mediante saggio ELISA gli analoghi strutturali del 
4-23-5, cioè il monomero, il dimero e il trimero con sequenza 4-23-5. Il saggio funzionale 
ha dimostrato che  la struttura  tetramerica è essenziale per  l’attività  inibitoria del peptide, 
infatti solo il tetramero è capace di dare inibizione, il trimero che manca di una sola 
sequenza tri-peptidica mostra una considerevole perdita di attività, mentre il dimero ed il 
monomero non presentano attività. 
Prima di usare il peptide in saggi su colture cellulari, è stata verificata la sua stabilità alle 
proteasi. Una quantità nota di peptide è stata incubata con siero fetale bovino al 10%, 
quindi è stata misurata la concentrazione peptidica nel tempo mediante cromatografia 
HPLC. Il peptide 4-23-5 mostra stabilità fino a 24 ore di incubazione (24 è il tempo 
massimo analizzato) come atteso avendo usato aminoacidi non naturali. 
Il peptide selezionato è stato usato per valutare la capacità di inibire la fosforilazione del 
recettore Flt-1. La stimolazione con PlGF (10 ng/ml) per 10 minuti di cellule 293 over-
esprimenti il recettore Flt-1, è capace di indurre un’elevata fosforilazione di tale recettore, 
dovuta alla maggiore affinità che tale proteina presente per Flt-1 rispetto a VEGF-A. Il 
peptide selezionato è stato usato a due diverse concentrazioni 4.0 e 20 M insieme a 
PlGF. Dopo la stimolazione le cellule sono state lisate e il recettore Flt-1 è stato immuno-
precipitato dal lisato proteico totale, quindi mediante western blotting è stata valutata la 
percentuale di recettore fosforilato rispetto alla quantità totale di recettore. Il peptide 4-23-5 
è in grado di inibire la fosforilazione di Flt-1 indotta da PlGF in maniera dose-dipendente, 
inibendo quindi il primo evento molecolare che attiva la trasduzione del segnale attraverso 
il recettore Flt-1 e che attiva la risposta angiogenica. 
Il peptide individuato è stato successivamente usato nel saggio di capillary-like tube 
formation (CTF) per valutare la capacità di inibire l’angiogenesi in vitro su cellule, e sia nel 
saggio di angiogenesi della membrana corioallantoidea dell’embrione di pollo (CAM) che 
nel saggio di neo-vascolarizzazione della cornea (CNV). per valutare la sua attività in vivo. 
Il saggio CTF è ampiamente utilizzato per testare la capacità angiogenica o anti-
angiogenica di sostanze: cellule endoteliali primarie cresciute su un supporto costituito da 
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estratti di matrice extracellulare (Matrigel) in presenza di specifici fattori di crescita, sono in 
grado di formare una rete di capillari primitivi. Esperimenti preliminari hanno dimostrato 
che i fattori PlGF e VEGF-A usati su cellule endoteliali umane del cordone ombelicale 
(HUVEC), ad una concentrazione di 100 ng/ml, sono capaci di indurre la formazione di 
una rete di capillari. Il peptide 4-23-5 è capace di inibire la formazione di tale 
organizzazione indotta sia da PlGF che da VEGF-A, mostrando  un’attività  dose-
dipendente. 
Nel saggio CAM, sfere pre-adsorbite con VEGF-A sono state poste sulla membrana 
corioallantoidea  dell’embrione  di  pollo  all’undicesimo  giorno  di  sviluppo,  l’attività 
angiogenica di VEGF-A viene valutata dopo dopo 72 ore dall’impianto contando il numero 
di  vasi  che  convergono  verso  l’impianto  stesso.  In  tale  saggio  è  stata  utilizzata  solo  la 
proteina VEGF-A capace di indurre angiogenesi agendo su entrambi i recettori Flt-1 e Flk-
1. Il peptide 4-23-5 è stato usato insieme a VEGF-A per valutare la capace di inibire 
l’attività  pro-angiogenica di questa. I risultati ottenuti mostrano che il peptide selezionato è 
in grado di  inibire  l’attività di VEGF-A in maniera dose-dipendente, dando una completa 
inibizione con 0.25 nmol mentre 0.025 nmol sono  in gradi di dare un’inibizione del 30%. 
L’attività osservata è specifica in quanto un peptide tetramerico di controllo non è capace 
di dare inibizione. 
Recentemente è stato dimostrato il ruolo della forma solubile di Flt-1 nel prevenire la 
vascolarizzazione  della  cornea.  L’assenza  di  vascolarizzazione  della  cornea  è 
fondamentale  per  l’ottimale  trasparenza  ottica  e  per  una  visibilità  chiara,  quindi  in  tale 
tessuto esiste un preciso meccanismo molecolare che in condizioni fisiologiche previene 
l’angiogenesi.  Nella  cornea  è  presente  una  grande  quantità  di  forma  solubile  di  Flt-1 
mentre è assente la forma di membrana, è inoltre presente VEGF-A ma è assente il 
recettore Flk-1. In condizioni fisiologiche Flt-1 solubile è capace di titolare VEGF-A 
impedendogli di stimolare le cellule endoteliali della sclera (che esprimono Flk-1), 
inducendo angiogenesi nel tessuto. Tale meccanismo è stato dimostrato mediante 
l’utilizzo  dell’anticorpo  anti-Flt-1,  infatti  l’iniezione di questo nella cornea induce 
angiogenesi. Sulla base di tale modello, la cornea risulta essere la piattaforma ideale per 
analizzare molecole anti-Flt-1, infatti una molecola capace di legare tale recettore, iniettata 
nella cornea, è capace di sequestrare Flt-1 solubile inducendo angiogenesi. 
Paradossalmente una molecola capace di legare Flt-1, quindi con attività anti-angiogenica, 
nella cornea risulta essere pro-angiogenica. Allo scopo di valutare la specificità del 
tetramero selezionato per Flt-1, sono state iniettate nella cornea di topi Balb/c 0.4, 4.0 e 20 
nmol di peptide bloccante e 20 nmol di peptide tetramerico di controllo. Dopo 7 giorni dalle 
iniezioni, è stata osservata la formazione di nuovi vasi, i topi sono stati sacrificati e da 
questi è stata isolata la cornea. I vasi formati in seguito ad angiogenesi sono stati 
individuati  mediante  l’analisi  di  immunofluorescenza  usando  quale  marcatore  CD31, 
specifico per le cellule endoteliali, mentre i vasi linfatici sono stati evidenziati usando come 
marcatore Lyve-1,  che  marca  solo  le  cellule  linfatiche.  L’analisi  ha  dimostrato  che  il 
peptide 4-23-5 è capace di indurre vascolarizzazione della cornea in maniera dose-
dipendente  e  l’attività  osservata  è  specifica  in  quanto  il  peptide  tetramerico  di  controllo 
anche se usato alla più alta quantità (20 nmol) non mostra nessuna induzione. Tale 
risultato conferma la specificità del peptide nel legare solo il recettore Flt-1 e non Flk-1, 
precedentemente osservata in vitro nei saggi ELISA eseguiti con il peptide immobilizzato. 
Inoltre  la  presenza  nella  cornea  dei  nuovi  vasi  ancora  dopo  7  giorni  dall’iniezione, 
conferma l’elevata stabilità del peptide già osservata in vitro. Infine, nei topi trattati con 20 
nmol di peptide bloccante è stata riscontrata una notevole formazione di nuovi vasi 
linfatici, tale osservazione è in accordo con recenti risultati che dimostrano la capacità di 
VEGF-A di indurre linfoangiogenesi. 
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I risultati ottenuti mostrano chiaramente che il peptide selezionato attraverso la 
deconvoluzione di una collezione tri-peptidica tetramerica formata inizialmente da 27000 
molecole, è capace di legare il recettore Flt-1 impedendo il legame dei suoi ligandi, PlGF e 
VEGF-A con il recettore Flt-1. La molecola selezionata è stabile nei confronti delle proteasi 
e inoltre non precipita in siero, proprietà che gli consentono di essere utilizzato in vivo. 
Inoltre è capace di inibire la fosforilazione di Flt-1 indotta da PlGF bloccando la cascata di 
trasduzione del segnale che porta alla risposta angiogenica mediata dal recettore Flt-1.  
I risultati ottenuti nel saggio di CTF e nel saggio CAM dimostrano che l’inibizione della sola 
fosforilazione di Flt-1 è sufficiente a bloccare l’attività pro-angiogenica di VEGF-A in vivo e 
in vitro. Infine i risultati del saggio di CNV dimostrano la specificità del peptide per il 
recettore Flt-1. 
Tali risultati dimostrano che il peptide 4-23-5 è un antagonista di Flt-1 e può essere 
utilizzato nella cura di quelle patologie caratterizzate da un’alterata angiogenesi.  
Sulla base del ruolo di Flt-1 sia nelle patologie infiammatorie quali arteriosclerosi e artrite, 
che nel processo di metastatizzazione, tale molecola potrebbe essere usata anche nella 
cura di tali patologie.  
Inoltre il peptide selezionato rappresenta un modello molecolare per la progettazione di 
nuovi peptidi ad attività maggiore nei confronti del recettore Flt-1. 
Tale  lavoro  dimostra  anche  che  l’approccio  biotecnologico,  mediante  l’introduzione  sia 
delle tecniche sintetiche che permettono di realizzare collezioni sempre più numerose e 
con elevata diversità chimica, che dello sviluppo di metodiche sperimentali che rendono 
l’analisi delle collezioni accurata e veloce, ha rivoluzionato la ricerca di nuove molecole di 
interesse  farmacologico.  Infatti,  rispetto  all’approccio  classico  che  prevede  l’analisi  di 
molecole derivanti da svariati sistemi viventi quali piante, microorganismi e animali, 
l’approccio biotecnologico consente di razionalizzare il processo di selezione e allo stesso 
tempo aumentare il numero di molecole analizzate. 
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2.1 Vasculogenesis and angiogenesis 
The vascular system is one of the most important apparatus of an organism. It provides 
oxygen and nutrients to all tissues removing the metabolic discards. The vascular system 
is generated by two different processes: vasculogenesis and angiogenesis. The term 
vasculogenesis indicates the formation of new blood vessels from endothelial precursor 
cells (EPCs). During development hemangioblasts, a mesodermal common precursor of 
endothelial and hematopoietic stem cells (HSCs), aggregate to form the blood islands. 
These structures proliferate and migrate to form a network of tubular structures 
characterized by two layers: the internal layer becomes the endothelial coating of the 
nascent vessels, while the external layer differentiate to smooth muscular cells (SMCs) or 
pericytes. Between them there is the basal lamina rich in collagen. The fusion of blood 
islands forms the primitive vascular plexus, in which the venous and arterial systems are 
already distinct tanks to molecular signaling of Eprin family members [1]. This distinction is 
revealed by expression on arterial cells of a transmembrane ligand, ephrinB2, whereas its 
receptor EphB4 is expressed on venous cells [2]. Moreover, recent data demonstrate that 
ephB2/EphB4 signaling plays an important role in vascular development, especially in the 
determination and boundary formation between arteries and veins [3]. The vascular plexus 
is immature and fragile and it needs of the angiogenic process to be stabilized. 
Angiogenesis is the formation of new blood vessels from pre-existing vessels. It is a 
complex process divided in two phases. The process starts with the activation of ECs by 
several stimuli such as hypoxia and ischemia. Hypoxia is an important stimulus for 
expansion of vascular bed. Initially, cells are oxygenated by simple diffusion of oxygen, but 
when tissues grow beyond the limit of oxygen diffusion, hypoxia triggers vessel growth by 
signaling through hypoxia-inducible transcription factors (HIF). HIFs up-regulates many 
angiogenic genes, such as VEGFs, angiopoietins, fibroblast growth factors and their 
various receptors, but the induction of VEGF is perhaps the most remarkable-up to 30-fold 
within minutes. Moreover genes involved in matrix metabolism, including matrix 
metalloproteinases, plasminogen activator receptors and inhibitors, and collagen prolyl 
hydroxylase are also regulated [4]. Vessels are destabilized and increase their 
permeability. This process requires the breakdown by proteinases, including plasminogen 
activator, metalloproteinases, heparinases, chymases, tryptates and cathepsyns. The ECs 
can migrate to the sites where angiogenesis is required, where they proliferate and 
differentiate. 
In the second phase there are the blocking of migration and proliferation processes and 
ECs form a new network of vessels. The new vascular network is stabilized from the 
addiction of several layers of SMCs that cover vessels. Finally the blood flow can start [5] 
(Fig. 1). 
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Fig.1: formation of a vascular network. A partial list of molecules is indicated [5] 
 
 
2.2 Pathological angiogenesis 
Pathological angiogenesis is characterized from an excessive or an insufficient vessels 
formation and is involved in a long list of disorders. The best known diseases 
characterized by abnormal angiogenesis are cancer, psoriasis, arthritis and blindness, but 
many additional common disorders such as obesity, asthma, atherosclerosis and 
infections disease are included and the list is still growing (Table 1). In addition, abnormal 
vessel obstruction or regression not only cause heart and brain ischemia, but can also 
lead neurodegeneration, hypertension, pre-eclampsia, respiratory distress, osteoporosis 
and other disorders (Table 2).  
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Table 1: Diseases characterized or caused by abnormal or excessive angiogenesis 
Organ Diseases in mice or humans 
Numerous organs Cancer(activation of oncogenes, loss of tumor 
suppressor); infectious diseases(pathogens 
express angiogenic genes, induce angiogenic 
programs or transform ECs); autoimmune 
disorders(activation of mast cells and leukocytes) 
Blood vessels Vascular malformation(Tie-2 mutation); DiGeorge 
syndrome(low VEGF and neuropilin-1 
expression); HTT(mutation of endoglin or Alk-1); 
cavernous hemangioma(loss of Cx37 and Cx40); 
atherosclerosis; transplant arteriopathy 
Adipose tissue Obesity (angiogenesis induced by fatty diet; 
weight loss by angiogenesis inhibitors) 
Skin Psoriasis, warts, allergic dermatisis, scar keloids, 
pyogenic granulomas, blistering disease, Kaposi 
sarcoma in AIDS patient 
Eye Persistent hyperplastic vitreous syndrome(loss of 
Ang-2 or VEGF164); diabetic retinopathy; 
retinopathy of prematurity; choroidal 
neovascularization(TIMP-3 mutation) 
Lung Primary pulmonary hypertension(germline 
BMPR-2 mutation; somatic EC mutations); 
asthma; nasal polyps 
Intestines Inflammatory bowel and periodontal disease, 
ascites, peritoneal adhesions 
Reproductive system Endometriosis, uterine bleeding, ovarian cysts, 
ovarian hyperstimulation 
Bone, joints Arthritis, synovitis, osteomyelitis, asteophyte 
formation 
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Table 2: Diseases characterized or caused by insufficient angiogenesis or vessel regression 
Organ Disease in mice or humans 
Nervous system Alzheimer disease 
 Amyotrophic lateral sclerosis; diabetic 
neuropathy 
 Stroke 
Blood vessels Atherosclerosis 
 Hypertension 
 Diabetes 
 Restenosis 
Gastrointestinal Gastric or oral ulcerations 
 Crohn disease 
Skin Hair loss 
 Skin purpura, telangiectasia and venous lake 
formation 
Reproductive system Pre-eclampsia 
 Menorrhagia(uterine bleeding) 
Lung Neonatal respiratory distress 
 Pulmonary fibrosis, emphysema 
Kidney Nephropathy 
Bone Osteoporosis, impaired bone fracture healing 
 
On the base of these evidences, angiogenesis represents an ideal therapeutic target of 
described diseases, indeed in the last decade the concept of angiogenic therapy has been 
developed with the aim to individuate new modulators able to inhibit excessive vessel 
growth or to stimulate angiogenesis [5]. 
 
2.3 The concept of angiogenic switch 
During development and after birth, blood vessels provide the growing organs with 
necessary oxygen and nutrients to develop. During adulthood, most blood vessels remain 
quiescent and angiogenesis occurs only in the cyclic ovary and in placenta during 
pregnancy. Moreover, ECs maintain their ability of dividing rapidly in response to stimulus, 
such as hypoxia for blood vessels and inflammation for lymph vessels. Angiogenesis is 
regulated from several pro- and anti-angiogenic factors, the balance between them 
prevents angiogenic process. In many disorders pro-angiogenic stimulus becomes 
excessive destroying the balance and inducing angiogenesis (angiogenic switch). Tumor is 
one of the best known condition in which angiogenesis is switch on. Several studies 
demonstrate that tumor cells induce angiogenesis through the secrection of pro-
angiogenic factors. Moreover, the inhibition of these factors causes a decrease of tumor 
vascularization and consequent reduction of tumor growth [6]. Neoplastic cell population 
can only form a clinically observable tumor if the host produces a vascular network 
New inhibitors of pathological angiogenesis 
 
15 
 
sufficient to sustain their growth. Furthermore, new blood vessels provide them a gateway 
trough which enter the circulation and metastasize distant sites. 
 
2.4 Molecular bases of angiogenesis 
Angiogenesis is a complex process, involving multiple gene products expressed by 
different cell types, all contributing to an integrated sequence of events. Since the 
complexity of angiogenesis, the molecular mechanisms involved in induction and 
regulation of angiogenic process are in part characterized and the list is still growing. 
Nevertheless, a large number of molecular factors that play a crucial role has been 
identified on the base of studies performed in vivo,on model organisms, and in vitro, on 
ECs systems. One of the most important and more characterized growing factors family is 
the Vascular Endothelial Growth Factor (VEGF) family. 
 
2.5 VEGF family 
The VEGF family plays an integral role in angiogenesis, lymphangiogenesis, and 
vasculogenesis. The family comprises seven proteins that are designated VEGF-A, VEGF-
B and PlGF (Placental Growth Factor) involved in angiogenesis, VEGF-C, VEGF-D that 
take place in lymphagiogenesis and VEGF-E and VEGF-F recently isolated which 
biological function are not well known. All factors are biologically active as secreted 
dimeric and glycosilated proteins, characterized by a conserved structural motif known as 
cysteine knot. The VEGFs exert their biologic effect through interaction with specific 
tyrosine kinases receptors. The binding of ligands to their extracellular domain induces the 
dimerization and autophosphorylation of the intracellular receptor tyrosine kinases. The 
receptors identified so far are designed VEGFR-1 (also known Flt-, fms-like tyrosine 
kinase), VEGFR-2 (named KDR (kinase domain receptor) in human and Flk-1 (Fetal liver 
kinase-1) in mouse), VEGFR-3 (also known Flt-4). In angiogenesis system, VEGF-A binds 
to both receptors Flt-1 and KDR/Flk-1 inducing vasculogenesis and angiogenesis. In 
contrast, PlGF and VEGF-B bind exclusively to Flt-1. PlGF shows more affinity for receptor 
than VEGF-A. VEGF-C and VEGF-D bind to KDR/Flk-1 and Flt-4 inducing 
lymphangiogenesis. Moreover, VEGF-A and PlGF also bind  the co-receptors Neuropilins 
(NP-1 and NP-2) but the molecular pathways activated has not been fully characterized 
(Fig.2) [7].  
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Fig.2: Interaction of VEGF family members with the VEGFR-1, -2 and -3, and Neuropilins-1 and -2. 
 
a) VEGF-A 
VEGF-A is the best characterized and the most studied VEGF family member. The VEGF 
gene which is composed of eight exons and is differentially spliced generates four mature 
isoforms (VEGF121, VEGF165, VEGF189 and VEGF206) [8]. The numeric designation of 
the isoforms denotes the number of amino acids composing the molecule. In addition, 
some less commonly expressed isoforms were identified (VEGF145 and VEGF183) [9]. 
VEGF165 is the predominant isoform. VEGF-A exerts its biologic effect through interaction 
with cell-surface receptors Flt-1and KDR/Flk-1, selectively expressed on vascular 
endothelial cells, and the Neuropilin co-receptors (NP-1 and NP-2), expressed on vascular 
endothelium and neurons [10] (Fig. 2). In vivo, VEGF-A expression has been shown to be 
associated with significant steps in angiogenesis and vasculogenesis [11]. Deletion of a 
single allele of  VEGF-A gene causes embryonic lethality due to vascular defects and 
cardiovascular abnormalities [12]. Transgenic mice, over-expressing VEGF-A in the skin, 
have abundant cutaneous angiogenesis and a psoriasis-like skin condition [13] and 
develop experimental tumor that growth more rapidly than in wild type mice  [14]. In 
contrast, mice with a mutated VEGF-A exhibit delayed wound healing [15]. Moreover,  
VEGF-A is expressed in practically all solid tumors studied as well as in some 
hematological malignancies [16], indeed correlations have been found between the level of 
VEGF-A expression, disease progression and survival of several cancers [14]. VEGFR-2 
appears to be the main receptor responsible for mediating the pro-angiogenic effects of 
VEGF-A [16]. VEGF-A is the most potent pro-angiogenic protein described to date. It 
induces proliferation, sprouting and tube formation of endothelial cells (ECs) [16]. It is also 
a potent survival factor for ECs and has been shown to induce the expression of anti-
apoptotic proteins in these cells [17]. In hypoxic condition VEGF-A transcription is strongly 
up-regulated by HIF-1 [18], mRNA stability is increased by binding of proteins to specific 
sequence  in  the  3’UTR  [19],  and  an  internal  ribosomal  entry  site  allows  preserved 
translation in the face of normal cellular hypoxic shutdown [20]. The biological activity of 
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secreted VEGF-A is further influenced by hypoxia-inducible expression of Flt-1 receptor 
[21] inducing an up-regulation of soluble Flt-1 [22] which inhibits VEGF activation, and 
post-transcriptional regulation of KDR/Flk-1 receptor [23]. 
VEGF-A also causes vasodilatation by inducing the endothelial nitric oxide synthase and 
so increasing nitric oxide production [24]. It induces HSC mobilization from the bone 
marrow, monocyte chemoattraction and osteoblast-mediated bone formation [16]. Many 
cytokines including platelet-derived growth factor, basic fibroblast growth factor, epidermal 
growth factor and transforming growth factors induce VEGF-A expression in cells [25]. 
 
b) PlGF 
PlGF was originally discovered in placenta [26] but it is also expressed in heart and lungs 
[27]. PlGF gene transcripts two isoforms named PlGF-1 and -2 by alternative splicing 
process. They differ in size, PlGF-2 contains a sequence of 21 aminoacids that confers it 
the ability to bind heparan sulfate proteoglycans [28]. 
PlGF binds specifically to Flt-1 with strong affinity than VEGF-A and VEGF-B. Activation of 
Flt-1 by either PlGF or VEGF-A induce different gene expression profiles reflecting the 
different phosphorylation pattern in the tyrosine kinase domain of Flt-1 [29]. Moreover, if 
co-expressed from the same cells, PlGf and VEGF-A can form an heterodimers able to 
bind Flt-1 or to induce Flt-1-KDR/Flk-1 heterodimerization [30]. Autiero et al have 
demostrated that both PlGF and PlGF/VEGF-A heterodimers can lead the transactivation 
of Flk-1 through Flt-1 activation enhancing the response to VEGF-A.  
PlGF knockout mice do not have an evident phenotype. They born at a mendelian 
frequency and are healthy and fertile. However, these mice present an impaired 
pathological angiogenesis as demonstrated in different models of diseases like cancer, 
diabetic retinopathy and myocardial infarct. Moreover healing of skin incisions progressed 
more slowly in PlGF knockout mice versus wild-type, while collateral growth model reveals 
an enlarged and tortuous collateral growth in wild-type but not in PlGF deficient mice, and 
this phenotype is accompanied from a reduced macrophages infiltration. The absence of 
PlGF also causes a reduced plasma extravasation [31]. Overexpression of PlGF in the 
skin of transgenic mice results in a significant increase in the number and size of skin 
blood vessels as well as in enhanced vascular permeability [32]. Conversely, PlGF 
deficiency resulted in a diminished and abbreviated inflammatory response, together with 
a reduction of inflammatory angiogenesis and edema formation [33]. 
These data indicate that PlGF is involved only in pathological angiogenesis and not in 
physiological angiogenic process. 
 
c) VEGF-B 
The human VEGF-B gene contains eight exons and six introns. The promoter region of 
VEGF-B gene contains some important differences relative to those of VEGF-A, and these 
are likely to explain differences in regulation by physiological stimuli [34]. The VEGF-B 
promoter lacks HIF-1 sites found in the VEGF-A promoter. Accordingly, hypoxia, which 
can induce VEGF-A expression, does not appear to regulate levels of VEGF-B [35]. 
VEGF-B gene expresses two isoforms VEGF-B167 and VEGF-B186 generated as a result of 
alternative splicing process. These proteins contain an identical 116 aminoacid N-terminal 
region, that includes the receptor binding domain. The C-terminal region differs between 
them and affects their distribution in the body. VEGF-B167 has a C-terminal heparin binding 
domain, thus it is associated with cell surface, in contrast, VEGF-B186 does not bind 
heparin and is thus likely to circulate freely. VEGF-B binds to Flt-1 receptor, since the 
activation of Flt-1 induces a poor mitogenic signal for ECs, VEGF-B is an inefficient EC 
mitogen [36]. 
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In vivo, VEGF-B is highly expressed in striated muscle, myocardium and brown fat [37]. 
Moreover, VEGF-B levels increase both throughout development and after birth, closely 
correlating with the progression of cardiac angiogenesis [38]. Mice deficient in VEGF-B 
present smaller heart size and impaired recovery after experimentally induced myocardial 
infractions suggesting that the regeneration of coronary collaterals through arteriogenesis 
could at least in part dependent on VEGF-B [38]. VEGF-B might have a role also in 
inflammatory angiogenesis ad demonstrated by knockout mice which displayed reduced 
angiogenic response in collagen-induced arthritis [39]. In pathology, high levels of VEGF-B 
expression were associated with metastasis to lymph node in colorectal cancer. Future 
studies should provide a more comprehensive understanding of the role of VEGF-B in 
cancers to validate it as a therapeutic target. 
 
d) VEGF-C 
VEGF-C is produced as a precursor protein, which is activated by intracellular secretory 
proprotein convertases furin, PC5 and PC7 [40].  
During development VEGF-C is expressed along its receptor Flt-4 mainly in regions where 
lymphatic vessels develop [41]. The expression then decrease in most tissue, remaining 
high in lymphatic nodes. VEGF-C induce selectively lymphangiogenesis without 
accompanying angiogenesis as demonstrated by early experiments in transgenic mice. 
Mice lacking both VEGF-C alleles showed failure in lymphatic vessels development and 
they died of edema [41]. Likewise, loss of one VEGF-C allele results in lymphedema 
characterized by hypoplasia of the cutaneous lymphatic vessels indicating that the VEGF-
C protein concentration is imperative for the development of the lymphatic vasculature 
[41]. VEGF-C mRNA transcription is induced in ECs in response to pro-inflammatory 
cytokines indicating that it could regulates lymphatic vessel function during inflammation 
[41]. This evidence reflects the role of the lymphatic vasculature in the control of immune 
function and leukocyte trafficking. VEGF-C is also chemotactic for macrophages and its 
receptor Flt-4 is expressed by a fraction of peripheral blood monocytes and activated 
tissue macrophages [42]. Moreover, several clinicopathological studies of cancer patients 
have demonstrated a correlation between VEGF-C expression and lymphatic invasion by 
metastatic cells [43, 44]. 
 
e) VEGF-D 
VEGF-D is closely related to VEGF-C by virtue of the unique presence of N- and C-
terminal extentions that other VEGF family members lack [45]. It binds to and activates 
KDR/Flk-1 and Flt-4 stimulating growth of vascular and lymphatic ECs in vivo [46]. VEGF-
D is present in most human tissues, most abundantly in the lungs and skin during 
embryogenesis. In experimental tumors VEGF-D plays a pivotal role in stimulating 
lymphangiogenesis and lymphatic metastasis [47]. VEGF-D is expressed by many tumor 
types and has been proposed to have a role in tumor angiogenesis and 
lymphangiogenesis in melanoma, pancreatic cancer, esophageal squamous cell 
carcinoma, breast cancer and lung cancer. 
 
f) VEGF-E 
The VEGF-E members show only 20% to 25% amino acid identity with VEGF-A. The first 
isoform of VEGF-E is the VEGF-ENZ-7 which is encoded by the Pox viruses of the Orf family 
[48]. This ligand specifically binds at high affinity and activates KDR/Klk-1 resulting in 
receptor autophosphorylation and rise in free intracellular Ca2+ concentration [49]. VEGF-
E can stimulate angiogenesis efficiently. Two other VEGF-E family members, VEGF-ENZ-2 
and VEGF-ED1701 were also isolated, both with essentially the same activity as that of 
VEGF-ENZ-7 [50, 51]. One significant characteristic of VEGF-ENZ-7 is its very strong affinity 
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to KDR/Flk-1 and ability to induce significant angiogenesis in vivo with few side effects. 
Thus, VEGF-E family members should be carefully studied as candidates for a potential 
angiogenic factor for clinical use in pro-angiogenic therapy . 
 
g) VEGF-F 
Recently a seventh member of the VEGF family with unique properties, VEGF-F, was 
identified from snake (viper) venom. VEGF-F consists of two VEGF-related proteins 
designated vammin (110 residues) and VR-1 (109 residues) that have a 50% structure 
homology with VEGF165 and bind selectively to VEGFR-2. VEGF-F was found to exhibit 
potent biological activity both in vitro and in vivo when compared with VEGF165 [52]. 
VEGF-F contains a short C-terminal heparin-binding region and the C-terminal peptide of 
VEGF-F exhibits a specific blockage of VEGF-A165 activity both in vitro and in vivo [53]. 
 
h) VEGFR-1 (Flt-1) 
Flt-1 (fms-like tyrosine kinase; Flt-1) is composed of seven extracellular immunoglobulin 
(Ig) like domains, a single transmembrane region and an intracellular tyrosine kinase 
domain [54]. VEGFR-1 is recognized by VEGF-A, VEGF-B and PlGF, showing the highest 
affinity for PlGF. During development, it is expressed less strongly than KDR/Flk-1, in 
angioblasts and in the endothelium. Its expression subsides during later embryonic stages 
[55, 56]. VEGFR-1 is expressed in ECs as well as in monocytes/macrophages [57], 
placental trophoblasts, osteoblasts renal mesangial cells [58], smooth muscle cells [59] 
and also in bone marrow stem/progenitors derived cells [60] and its expression is up-
regulated by hypoxia via a HIF-1-dependent mechanism [21]. Flt-1 null mutant mice die at 
embryonic stage E 8.9-9.0 due to the over-growth and disorganization of blood vessels 
[56] suggesting Flt-1 involvement in reorganization and stabilization of primitive vascular 
plexus. In contrast mice lacking the tyrosine kinase domain of Flt-1 are vital and fertile but 
in these mice the tumor growth and tumor angiogenesis are inhibited, suggesting that the 
tyrosine kinase domain is required for pathological angiogenesis. The activation of Flt-1 by 
PlGF, is not only crucial for ECs stimulation during neo-angiogenesis process, but plays a 
fundamental role also in stabilization of neo-vessels trough the recruitment of SMC and in 
the recruitment and differentiation of monocyte-macrophage cells [31], [61]. Recent studies 
have emphasized the effects of VEGFR-1 in hematopoiesis and recruitment of endothelial 
progenitors. Hattori et al. have shown that PlGF promotes recruitment of VEGFR-1(+) 
HSCs from a dormant to a proliferative bone marrow environment, favoring differentiation 
and reconstitution of hematopoiesis [60]. Moreover, recently Kaplan et. al. have 
demonstrated the pivotal role of Flt-1 in the regulation of metastasis, they have published 
that Flt-1 marks bone-marrow derived haematopoietic progenitor cells that migrate to 
tumor-specific pre-metastatic sites and form cellular cluster before the arrival of tumor cells 
[62]. In fact, preventing VEGFR1 function using antibodies or by the removal of VEGFR1+ 
cells from the bone marrow of wild-type mice abrogates the formation of these pre-
metastatic clusters and prevents tumor metastasis. A naturally occurring, soluble form of 
VEGFR-1 (sFlt-1) exists and it could act as an efficient specific antagonist of VEGF-A, 
VEGF-B or PlGF. Soluble Flt-1 is expressed in several tumors, including astrocytic tumors 
and breast cancer, although its actual role in these tumors remains to be investigated [63]. 
Moreover, recently Ambati et. al. have demonstrated that sFlt-1 has a crucial role in the 
maintenance of corneal avascularity. In the cornea is absent the membrane bound form of 
Flt-1, while is present an high amount of sFlt-1 essential for preventing binding of VEGF-A 
to Flk-1 receptor expressed on conjunctiva creating an anti-angiogenic barrier. When an 
injury of cornea occurs, there is an increase of  VEGF-A level, it titles sFlt-1 and binds to 
Flk-1 inducing angiogenesis [64]. 
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i) VEGFR-2 (KDR/Flk-1) 
VEGFR-2 is known as KDR (Kinase Domain Receptor) in human and Flk-1(Fetal Liver 
Kinase-1) in mouse. Like Flt-1 it bears an extracellular region with seven Ig-like domains, a 
transmembrane domain and a tyrosine kinase domain with about 70-amino-acid insert. 
VEGFR-2 is recognized by VEGF-A, VEGF-C, VEGF-D and VEGF-E. It is expressed in 
ECs, neuronal cells, osteoblasts, megakaryocytes and hematopoietic stem cells [16], [65]. 
Flk-1 gene knock-out mice die at E8.0-8.5 due to a lack of vasculogenesis. This indicates 
that VEGFR-2 signaling is essential for the differentiation of VEGFR-2-positive endothelial 
precursor cells into vascular ECs and for their proliferation [66]. This process goes through 
the activation of the RAF-MEK-ERK pathway. Moreover, a role of VEGFR-2 in 
hematopoiesis has been described , indeed KDR has been identified on a subset of 
multipotent human HSCs [67]. Since KDR/Flk-1 is the main receptor for ECs proliferation 
and differentiation in response to VEGF-A, the first approach for anti-angiogenic therapy of 
tumor has been focalized to inhibit this pathway. At this regards, an humanized antibody 
against VEGF-A, bevacizumab (Avastin) is actually used in combination with 
chemotherapy [68]. 
 
j) VEGFR-3 (Flt-4) 
Flt-4 has only six Ig-homology domains [69] and it is recognized by VEGF-C and VEGF-D. 
In humans, Flt-4 expression was correlated with transient lymphangiogenesis in wound 
healing and was upregulated in blood vessel endothelium in chronic inflammatory wounds 
[70]. Thus, VEGFR-3 is believed to play various roles in cardiovascular development and 
remodeling of primary vascular networks during embryogenesis and enhancing 
lymphangiogenesis in adulthood. More interesting is its role in pathology, indeed VEGFR-3 
is distributed widely in vascular tumors and can be considered as a marker of endothelial 
cell differentiation of vascular neoplasms [71]. Moreover, Jennbacken et al. showed that 
increased expression of VEGF-C and VEGFR-3 plays a role in prostate cancer 
progression and lymph nodes metastasis [72] and its activation accompanied by 
upregulation of its ligands were also observed in melanoma and breast cancer [73]. 
Accordingly with these data, VEGFR-3 blockade significantly inhibited lymphangiogenesis 
and lymph node metastasis [72].  
 
k) Neuropilin-1 and -2 
Neuropilin NP-1 was identified initially as a cell-surface glycoprotein that served as a 
receptor for the semaphorin/collapsins, a large family of secreted and transmembrane 
proteins that serve as repulsive guidance signals in axonal and neuronal development 
[74], [75]. NP-1 binds VEGF-A and PlGF while NP-2 binds only VEGF-A (Fig. 2). During 
embryonic development, NP-1 is expressed in the nervous, cardiovascular, and skeletal 
systems [74], [76], whereas in adults it is also expressed in ECs, tumor cells, lung, heart, 
liver, kidney, pancreas, osteoblasts, and bone marrow stromal cells [77], [78]. NP-2 has a 
similar expression pattern. NP-1 acts as a co-receptor enhancing VEGF-A–VEGFR-2 
interactions, forming complexes with VEGFR-1 and augmenting tumor angiogenesis in 
vivo, while NP-2 is expressed on lymphatic ECs, and mutated NP-2 induces abnormalities 
in the formation of small lymphatic vessels and lymphatic capillaries in mice [79]. The role 
of NP-1 in the development of the vascular system has been demonstrated by gene-
targeting studies, documenting embryonic lethality in null mice [80]. Interestingly, recent 
studies have linked NP-2 to lymphatic vessel development [79]. 
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2.6 Molecules developed for angiogenic therapy: an overview 
In the last decade, the concept of angiogenic therapy has been developed as a strategy to 
treat cancer inducing the regression of vessels that provide sustenance of tumor mass. 
Recently, it has been re-defined and extended to all pathologies characterized from a 
reduced or excessive angiogenesis. Conseguently, more attention has been devoted to 
molecular factors with anti- or pro-angiogenic properties. Different biotechnological 
approaches like production of recombinant proteins and monoclonal antibodies, and 
identification of small interfering molecules have been used to search for modulators of 
angiogenesis pathways. Due to the biological and functional properties above described, 
VEGF-A and KDR/Flk-1 receptor have been chosen initially as preferential target for 
angiogenic therapy [81]. In fact, the first anti-angiogenic drug is the humanized monoclonal 
anti-VEGF-A blocking antibody Bevacizumab (Avastin, Genetech, Inc.) [68]. Although  it 
has showed encouraging results in patients with colorectal cancer, non-small cell lung 
carcinoma and breast cancer demonstrating that the angiogenic process could be a real 
target for cancer therapy, its activity is responsible for different undesired effects as 
thrombosis, pulmonary hemorrhage, hypertension and proteinuria [82], [83]. Moreover, 
Avastin alone did not show significant efficacy and it must be used in combination with 
traditional chemotherapy agents. Moreover, several classes of tyrosine kinase inhibitors 
have been developed [83] . These inhibitors are small molecules that bind to TP-binding 
site of the tyrosine kinase domain of VEGFRs, resulting in a blockade of intracellular 
signaling. In table 3 are reported the most important VEGFR small-molecule inhibitors, the 
specific molecular target, the activity in term of IC50, and the current phase of clinical 
development 
Table 3: VEGFR inhibitors, molecular targets, IC50 and phase of clinical development 
    IC50 M      
Agent Molecular 
target 
Flt-1 KDR/Flk-1 Flt-4 PDGFR- c-Kit Raf Flt-3 Developme
nt 
Vatalinib 
(PTK/ZK) 
VEGFR-1, -2, 
-3, PDGFR-
c-Kit 
0,077 0,037 0,66 0,58 0,73   Phase III 
Semaxanib 
(SU5416) 
VEGFR-1 and 
-2 
0,008 0,20 - 0,68 0,47 - - Stopped 
Sutinib 
(SU11248) 
VEGFR-1 and 
-2, PDGFR, c-
Kit, Flt-3 
0,002 0,009 0,017 0,002 0,0022 - 0,25 Phase III 
Sorafenib 
(BAY 43-
9006) 
VEGFR-2 and 
-3, RAF, 
PDGFR, c-Kit, 
RET 
- 0,09 0,02 0,057 0,068 0,006 - Phase III 
ZD6474 VEGFR-2, 
EGFR, FGFR-
1, RET 
1,6 0,04 0,11 1,1 ˃20 - - Phase II 
SU6668 VEGFR-2, 
PDGFR-
FGFR-1, c-
Kit 
- 2,1 - 0,008 0,1 - - Stopped 
AG-013736 VEGFR-1, -2, 
and -3, 
PDGFR-, c-
Kit 
0,0012 0,00025 0,00029 0,0025 0,0020 - - Phase I/II 
AZD2171 VEGFR-1, -2, 
and -3, 
PDGFR-, c-
Kit 
0,005 ˂0,001 ˂0,003 0,005 0,002 - ˃1 Phase I 
AEE788 VEGFR-1 and 
-2, EGFR 
0,059 0,077 0,33 0,32 0,70 2,8 0,73 Phase I 
 
New inhibitors of pathological angiogenesis 
 
22 
 
The major part of these molecules present an IC50 value in concentration range of nM, 
they are orally bio-available and all are in clinical trial of phase II o III. Unfortunately  all 
these molecules present a lot of side effects such as hypertension, nausea, vomiting, 
fatigue, proteinuria and much more [83] due to their wide range of specificity, in fact they 
act on a large number of receptors, some of them involved in different biological 
processes. 
 
2.7 PlGF/Flt-1 pathway: a new therapeutic target? 
The first target for angiogenic therapy has been VEGF-A and its receptor KDR/Flk-1. In 
fact, VEGF-A was initially used to stimulate the angiogenesis after ischemic injury [84]. 
The trials have been conducted either by administering recombinant proteins or by gene 
transfer using viral vectors or naked plasmids [85]. One of the major limitations in using 
VEGF-A for stimulation of angiogenesis is its potent activity on vascular permeability. High 
levels of circulating VEGF-A, such as those obtained in mice over-expressing VEGF-A or 
those produced by adenoviral gene transfer, cause leakly vessels associated lethal edema 
[86]. In a study conduced in patients with lower extremity ischemia, 34% of patients 
developed edema when treated with naked plasmid DNA encoding VEGF-A. This side 
effect was confined to patients with critical limb ischemia, while it was absent from less 
severely ill patients with stress-related ischemia [84]. On the other hand, results obtained 
with Avastin show that inhibition of VEGF-A alone did not resolve cancer as expected but it 
induces only a weak effect reducing the growth of cancer, moreover it is accompanied 
from several collateral effects due to the involvement of VEGF-A in different physiological 
process. These data demonstrate that interfering on VEGF-A/KDR/Flk-1 pathway 
stimulating or inhibiting it, nevertheless it produces expected angiogenesis affect, it causes 
important undesired effects. 
In contrast, data obtained on PlGF and Flt-1 demonstrate that their role is mainly confined 
to pathological angiogenesis. In Plgf -/- mice, pathological angiogenesis is inhibited. 
Tumors induced by inoculation of Plgf -/- embryonic stem (ES) cells are smaller and less 
vascularized than tumors induced by inoculating wild type ES and are comparable with 
VEGF-A deficient tumors induced by inoculation of Vegf -/- ES cells. Thus, the loss of PlGF 
inpairs the growth of VEGF-A-dependent tumors. At the same time, when conditions 
similar to the hypoxic ischemic retinopathy have been induced, the loss of PlGF 
significantly protects mice against intra-vitreous neo-vascularization, venous dilatation, and 
arterial tortuosness [31]. Thus, a physiological concentration of PlGF is still able to support 
this pathological events, since hypoxic conditions highly up-regulate VEGF-A, but not 
PlGF. At the same time, recombinant PlGF is able to stimulate neo angiogenesis in 
ischemic pathologies with an effect comparable to that observed with VEGF-A, without 
generate VEGF-A-induced side effect. This view is supported by the results obtained in 
mice lacking the tyrosine kinase domain of Flt-1, in which the tumor growth and tumor 
angiogenesis are inhibited, suggesting that the tyrosine kinase domain is strictly required 
for pathological changes. Flt-1 is also involved in the recruitment of both EPCs and SMCs 
and plays a pivotal role in the mobilization of bone marrow-derived myeloid progenitors 
into the peripheral blood, in the infiltration of Flt1-expressing leukocytes in inflamed tissues 
and in activation of myeloid cells [87]. These activities are crucial for a correct neo-
angiogenesis process. Indeed, neutralizing monoclonal anti-Flt-1 antibody are able to 
strongly prevent tumor angiogenesis, as well as inflammatory disorders and tumor 
metastasis [62]. All together these data indicate that modulation of the PlGF/Flt-1 pathway 
could be an innovative and advantageous therapeutic target to treat pathological 
angiogenesis. 
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2.8 Aims of the study 
In order to identify new modulators of pathway activated by interaction of VEGF family 
members with Flt-1 receptor, we planned to screen combinatorial peptide libraries. 
The aim of this study is the identification of small molecules able to interfere in the 
VEGFs/Flt-1 interactions, in order to prevent the biological response of this pathway in the 
pathological angiogenesis. 
Combinatorial chemistry has been widely employed for creating a number of different 
compounds simultaneously and screening rapidly for the identification of active 
compounds and is regarded as a powerful tool for the discovery of new drugs, catalysts 
and materials [88]. 
Among the wide libraries possibility, combinatorial peptide libraries have been the most 
developed and their synthesis is fully automated. The chemical properties and the 
elevated number of aminoacids (natural and modified) allow the realization of several 
different structures such as linear, branched, cyclic or multimeric scaffolds, increasing the 
number of molecules to assay. The most important event for the development of 
combinatorial chemistry was the solid phase synthesis method, developed by R. B. 
Merriefeld [89]. Following on many research areas: solid supports, linkers and peptide 
coupling chemistry, automated synthesis, and screening methods have been developed 
[90]. Peptide libraries are largely utilized in drug discovery field for the easiness of 
preparation and purification and the robustness of the avaible chemistry. A peptide 
combinatorial library is a collection of several peptides that shared the same structure, the 
number of different obtained sequences depends both on the number of aminoacids used 
as building-blocks and on the peptide length, as reported in the following formula: N=bL, in 
which N is the number of different peptides, b is the number of building-blocks and L is the 
peptide length. Deconvolution methods of a peptide library evaluates the contribution of 
each residue for each sequence position activity of peptide. In this study we have 
screened combinatorial libraries. 
 
2.9 Biotechnological application 
The use of recombinant proteins and monoclonal antibodies in therapy has been one of 
the main successes of biotechnology both on research and industrial production aspects. 
Nonetheless their use in therapy is limited due to the high costs of production. 
Small molecules offer numerous advantages with respect to recombinant proteins. Low 
molecular weight often allows to escape recognition by the immunity system, small 
molecules can be more easily produced, and are generally free of contaminants of 
biological origin, they offer more opportunity for delivery allowing also oral administration 
and their costs of production are lower with respect to monoclonal antibodies or 
recombinant proteins.  
In this regard, in the last two-decade a great efforts has been done to realize large 
collections of small molecules for screening purpose as well as small molecules design 
based on molecular modeling. In vitro analysis of these collections n has been possible 
thanks to recombinant protein production ability. 
Among the opportunity to generate large collection of molecules, combinatorial chemistry 
has represented one of the main fields of application. Peptide combinatorial libraries 
represent one of the largely used approaches to search for modulators of protein-protein 
interaction. 
Biotechnology approaches have been developed to fully automate both synthesis of 
libraries and High-Throughput Screenings (HTS) approaches, which have enormously 
increased the capacity in term of number of molecules and time reduction for the analysis. 
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The identification of biologically active small molecule open new perspective in term of 
industrial biotechnological application, both on new process for active molecule production 
and the use of selected molecule as chemical scaffold to further develop the molecule in 
term of target affinity and specificity. 
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III. Results 
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3.1 Synthesis and screening of tetrameric tripeptide library 
In order to identify new peptides able to inhibit PlGF/Flt-1 interaction, it has been 
synthesized and screened a tetrameric tripeptide library which structure is shown in figure 
3. The library has been prepared using 29 non-naturals aminoacids plus Glycine (Table 4). 
Non-naturals aminoacids have been chosen from the D-aminoacids and modified L-
aminoacids to increase chemical diversity and protease resistance of peptides. The 
structure contains a lysine core to build the tetrameric scaffold. This structure has been 
adopted to increase the activity of the molecules that presented the same tripeptide 
sequence repeated four times (Fig. 3). 
 
 
 
Table 4: List of building blocks aminoacids used to generate tetrameric tripeptide library 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3-letters code building block 
D-Ala D-Alanine 
D-Arg D-Arginine 
D-Arg(Tos) D-Arginine(N -Tosyl) 
D-Asn D-Asparagine 
D-Asp D-Aspartic acid 
D-Cys(Acm) D-Cysteine(S-acetamydomethyl) 
D-Gln D-Glutamine 
D-Glu D-Glutamic acid 
D-His D-Histidine 
D-Ile D-Isoleucine 
D-Leu D-Leucine 
D-Lys D-Lysine 
D-Met D-Methionine 
D-Phe D-Phenylalanine 
D-Pro D-Proline 
D-Ser D-Serine 
D-Thr D-Threonine 
D-Trp D-Triptophan 
D-Tyr D-Tyrosine 
D-Val D-Valine 
Gly Glycine 
L-Cha L-Cyclohexylalanine 
L-Cys(Acm) L-Cysteine(S-acetamydomethyl) 
L-Cys(Bzl) L-Cysteine(S-benzyl) 
L-Cys(p-MeBzl) L-Cysteine(S-pmethyl-benzyl) 
L-Cys(tBu) L-Cysteine(S-tert-butyl) 
L-Glu(β-OAll) L-Glutamic acid-(β-allyl) 
L-Met(O) L-Methionine-sulphone 
L-Met(O)2 L-Methionine-sulphoxide 
β-Ala β-Alanine 
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Figure 3: Structure of tetrameric tripeptide library. X letter denotes the unknown aminoacids to 
determine by deconvolution process. 
 
 
 
The library was synthesized using the mix and split protocol [91] and after the first 
synthesis it was composed by 30 pools each of them contained 900 different peptides, 
realizing an initial complexity of 27,000 molecules. Pools differed only for the aminoacid in 
N-terminal position that varied among those chosen to synthesize the library, identifying 
the 30 pools, here indicated as pool 1 to pool 30. Peptide mixture were obtained in high 
yield (about 70%) as calculated assuming an average molecular weight of 2130 amu for 
each library component, and with an average purity of the crude products  >85% (as 
determined for the single molecules assayed during the last screening round, table 4). The 
LC-MS analyses of some selected 30-components mixtures showed that the expected 
molecules were all equally represented and MWs were in very good agreement with those 
calculated.  
Deconvolution of library was carried out by the iterative process [88] by an ELISA-based 
competition assay. In iterative approach a progressive selection is performed, choosing 
one aminoacid at a time for each position. Sequence of sub-libraries is dictated by the 
results of the previous one. ELISA-competition assay allows the identification of molecules 
able to inhibit the interaction of PlGF with the immobilized Flt-1 receptor. Screening was 
performed on PlGF/Flt-1 system because PlGF presents more affinity for Flt-1 than VEGF-
A. At every steps of screening, peptides pools were assayed with a molar excess of 1.000-
fold (calculated for each single peptide) over PlGF. In the first round of screening the pool 
with the aminoacid 4 in N-terminal position (pool 4-X-X, where X indicated all the possible 
aminoacids used for library synthesis), showed the best inhibition activity pwith a 
percentage of binding of 58% (Fig. 4). The active pool 4 was assayed in a dose-dependent 
competition assay using 500, 1.000, 1.500 and 2.000 fold excess and comparing it with 
pools 2 that showed about 20% of inhibition, and pool 14 that was inactive (Fig. 5). 
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Figure 4: First screening of tetrameric tripeptide library performed by ELISA- based competition 
assay. Histogram reports the percentage of binding of each pool calculated assuming the binding of 
PlGF to Flt-1 as the 100% of binding. Monoclonal anti-PlGF antibody was used as inhibition control. 
In red was reported pool showing the best inhibition. 
 
 
 
 
 
Figure 5: Dose-dependent ELISA-competition assay performed with positive pool 4 and pools 2 and 
14 used as negative control.  
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Based on the results obtained in first screening the analysis of library was continued 
synthesizing sub-libraries of generic sequence 4-B-X. This sub-library was made of 30 
pools, each of them containing 30 peptides, with the aminoacid 4 in N-terminal position, 
the second position (indicated as B), identify each pool with the 30 building-blocks used to 
synthesize the library, while the third position (indicated as X) was random. The pools 
were assayed by ELISA-competition assay using a molar excess of 1.000-fold (calculated 
for each single peptides) over PlGF (Fig. 6).  
 
 
 
 
Figure 6: Screening of tetrameric sub-library 4-B-X performed by ELISA competition assay. 
Histogram reports the percentage of binding of each pool calculated assuming the binding of PlGF to 
Flt-1 as the 100% of binding. Monoclonal anti-PlGF antibody was used as inhibition control. In red 
were reported pools showing best inhibitory activity. 
 
 
 
The pools labeled as 2, 9, 10, 14, 23, 26, 27 and 28, that presented the best inhibitory 
activity were assayed in a dose-dependent ELISA competition assay, using 1000 and 
10.000 fold excess comparing them with pool 4 of original library and pool 4 reconstituted 
mixing equal amounts of sub-libraries 4-B-X, as positive control (Fig. 7). 
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Figure 7: Dose-dependent ELISA assay performed with 4-B-X positive pools (2, 9, 10, 14, 23, 26, 27 
and 28) and controls (monoclonal anti-PlGF antibody, original pool 4 of B-X-X library, reconstituted 
pool 4) used at 1000 and 10.000 molar excess  
 
 
 
 
The second screening identified the aminoacid 23 as the most active residue in second 
position. Thus the pool 4-23-X showed the higher inhibition together with the best dose-
dependent profile. Finally, 30 single peptides of 4-23-X pool were synthesized. These 
peptides differed only for the third position, identified with the 30 building-blocks. The LC-
MS analyses of all 30 peptides showed that the expected molecular weights (MW) were in 
very good agreement with those calculated as reported in table 5.  
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Table 5: Characterization of the 30 single peptides assayed in the last screening. Theoretical MWs 
are calculated as average. MWs were obtained by LC-ESI-MS analysis of the crude products and 
were derived by the experimentally determined [M+2H]2+ values (3rd column). Product purities were 
determined by integrating chromatogram peaks on the 215 nm trace and excluding peaks within the 
first 5 minutes of the run. Data of the 4-23-5 peptide are in bold. 
 
Monomer n° Theor. MW (amu) Exp. [M+2H]2+ Exper MW (amu) Purity (%, HPLC) 
1 2033.46 1017.8 2033.6 87.5 
2 2209.50 1105.6 2209.2 88.9 
3 2145.66 1074.0 2146.0 95.3 
4 2265.58 1133.9 2265.8 97.5 
5 2362.02 1182.1 2362.2 90.5 
6 2387.82 1169.8 2337.6 86.0 
7 2153.54 1077.7 2153.4 88.7 
8 2273.90 1137.9 2273.8 83.7 
9 2446.02 1224.1 2446.2 84.5 
10 2261.82 1132.0 2262.0 98.0 
11 2401.82 1201.8 2401.6 90.4 
12 2137.58 1069.6 2137.2 91.0 
13 2201.78 1101.9 2201.8 83.9 
14 2297.70 1150.0 2298.0 86.2 
15 2261.66 1131.9 2261.8 89.0 
16 2493.98 1248.0 2494.0 79.8 
17 2373.90 1188.1 2374.2 85.9 
18 2205.54 1103.8 2205.6 89.1 
19 2201.78 1102.0 2202.0 95.2 
20 2990.62 1496.2 2990.4 82.9 
21 20.97.46 1049.8 2097.6 88.6 
22 2446.02 1224.0 2446.0 93.0 
23 2522.22 1262.1 2522.2 96.1 
24 2642.38 1322.2 2642.4 88.5 
25 2386.22 1194.1 2386.2 86.3 
26 2337.90 1169.8 2337.6 72.5 
27 2401.90 1201.9 2401.8 70.4 
28 2425.94 1213.9 2425.8 90.1 
29 2033.46 1017.7 2033.4 89.2 
30 1977.34 989.7 1977.4 96.5 
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Peptides were submitted to the screening (Fig. 8) and the most active peptide possess the 
residue 5 in this position. 
 
 
 
Figure 8: Third screening of 4-23-B peptides. Peptides were used at 1000x molar excess. Monoclonal 
anti-PlGF antibody, original pool 4-23-B and reconstituted 4-23-B pool from single peptides were 
used as positive controls of inhibition. In red are reported the most active aminoacids in third 
position 
 
 
The screening of tetrameric tripeptide library allowed the identification of the tetrameric 
tripeptide Gly-Lys(Lys2)-[4-23-5]4, named 4-23-5. These numbers represent the selected 
aminoacids for each position and reflects the code used to catalogue building-blocks 
aminoacids. The inhibition activity of 4-23-5 peptide was evaluated in a dose-dependent 
ELISA assay comparing it with the tetrameric tripeptides 4-23-A (Ala-scanning related 
peptide, see above) and an unrelated tetrameric tripeptide, 21-1-5, as controls. The 
selected 4-23-5 peptide was able to inhibits PlGF/Flt-1 interaction with an IC50 around 10 
M (Fig. 9). Since VEGF-A and PlGF interact in a very similar manner with Flt-1 receptor 
[92], the ability of 4-23-5 peptide to inhibit also VEGF-A/Flt-1 interaction was immediately 
investigated.  
As shown in figure 10, the selected peptide inhibits VEGF-A/Flt-1 interaction with similar 
extent with an IC50 around 10 m. 
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Figure 9: Dose-dependent inhibition of PlGF/Flt-1 interaction exerted by 4-23-5 peptide in competitive 
ELISA-based assay. Tetrameric 4-23-5, 4-23-A and 21-1-5 peptides were assayed at concentration 
ranging between 1.56 to 50 M. Results present the average of three independent experiments. 
 
 
 
 
 
Figure 10: Dose-dependent inhibition of VEGF/Flt-1 interaction exerted by 4-23-5 peptide. All peptides 
were assayed at concentration ranging between 1.56 to 50 M. Results present the average of three 
independent experiments. 
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3.2 Peptide activity is sequence and structure dependent 
In order to evaluate the relation between peptide activity and its aminoacidic sequence, the 
Ala-scanning protocol has been used. Ala-scanning method allows to determine which 
residues play a critical role in biological activity of peptide. For each aminoacid position 
was synthesized a variant with the substitution of a single residue with L-Alanine, while the 
others residues were unchanged. To this end, the Ala-scanning related peptides 4-23-A, 4-
A-23 and A-23-5 were assayed at a concentration of 50 M comparing them with 4-23-5 at 
a concentration of 12,5 M on both PlGF/Flt-1 and VEGF-A/Flt-1 systems (Fig. 11). 
Results demonstrated how each residues substitution determined the lost of peptide 
activity indicating that the selected residues are all necessary for peptide inhibitory activity. 
 
 
 
Figure 11: ELISA assay performed with Ala-scanning peptides on both PlGF/Flt-1 and VEGF-A/Flt-1 
systems. DMSO refers to absence of competitor, while * refers to 4-23-5 peptide used at a 
concentration of 12,5 M.  
 
 
 
Moreover, to evaluate the contribution of tetrameric structure on inhibitory activity of 4-23-5 
peptide, the structural analogues monomer, dymer, cyclic dymer and trimer of tetrameric 
peptide were synthesized. The cyclic dymeric analogue was synthesized to stabilized the 
dymeric form through its cyclization. This structure has been realized thanks to the 
introduction of two Cysteine residues at N-terminal positions. The oxidation of their SH-
groups occurs in acqueous solution and generates the desired cyclic structure. All 
analogues were assayed in ELISA competition assay at concentration of 50 M (Fig. 12), 
as well as performed with Ala-scanning peptides. 
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Figure 12: Structure analogues in ELISA competition assay. DMSO refers to absence of competitor, 
while * refers to 4-23-5 peptide used at a concentration of 12,5 M. 
 
 
The results showed how the 4-23-5 activity is closely dependent also on tetrameric 
structure. The loss of even a single tripeptide strand as well as in trimer 4-23-5, caused a 
great loss of inhibitory activity of tetrameric 4-23-5.  
 
 
 
 
 
3.3 4-23-5 peptide binds specifically to Flt-1 receptor 
To evaluate the molecular mechanism that lead peptide activity, it has been realized an 
ELISA-binding assay performed with peptide 4-23-5 coated on microtiter plate. The plate 
were incubate with recombinant soluble growth factors or receptors both of human and 
mouse origins. While the soluble factors VEGF-A and PlGF were unable to recognize 4-
23-5 or control peptides (data not shown), both human and mouse Flt-1 receptors were 
able to recognize the peptide in a dose-dependent manner (Fig. 13). The binding was 
specific since Flt-1 receptor did not recognize control peptides (Fig. 14). More important, 
KDR and Flk-1 receptors were unable to interact with control peptide  (Fig 15), indicating 
that 4-23-5 is specific for VEGFR-1 and do not interfere with VEGFR-2 activity. 
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Figure 13: Binding profile of human and mouse Flt-1 receptor on coated 4-23-5 peptide. The binding 
was dose-dependent as demonstrated both using a fixed concentration of coated peptide (20 M) 
and concentration ranging 50 to 400 pM of Flt-1 receptor (a) and using concentration ranging 0.1 to 2 
M of peptide in coating and a fixed concentration (125 pM) of Flt-1 in binding (b). 
 
 
 
A 
B 
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Figure 14: Binding of human and mouse Flt-1 receptors (250 pM) to coated 4-23-5 and control 
peptides at 20 M. 
 
 
 
 
 
 
Figure 15: Binding assay of both human and mouse Flt-1 and KDR/Flk-1 receptors at 125 and 250 pM 
to coated 4-23-5 peptide at 20 M. 
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3.4 Evaluation of 4-23-5 activity on cell-based assays 
 
Before assaying peptide in cell-based assay, it was evaluated its protease resistance over 
the time. Peptide was incubated in 10% fetal bovine serum for 24 hours, and peptide 
concentration was evaluated measuring the peak area corresponding to peptide on 
chromatographic profile at different times of incubation. As shown in figure 16 peptide was 
fully stable after 24 hours (Fig. 16). Moreover, this experiment also demonstrated that, 
under these conditions, the peptide did not bind to pelleted serum proteins. 
 
 
 
 
Figure 16: concentration profile of 4-23-5 peptide during 24 hours of incubation in 10%  fetal bovine 
serum. At the indicated times, aliquots were removed, centrifuged to remove proteins and analyzed 
by HPLC (10 µL, 1 µg). Peak area, expressed as the percentage of the initial amount, versus time was 
plotted. 
 
 
 
 
 
The neutralizing activity of 4-23-5 peptide was evaluated in the inhibition of Flt-1 receptor 
phosphorilation. PlGF added at 10 ng/ml was able to induce strong Flt-1 phosphorilation in 
stable 293 cell line over-expressing the receptor [93]. The addition of selected peptide with 
PlGF, was able to prevent PlGF-induced Flt-1 phosphorilation in a dose-dependent 
manner. The observed inhibition was total at a concentration of 20 M while control 
tetrameric peptide 4-23-A at same concentration did not show inhibition. At a concentration 
of 4 M peptide caused a partial inhibition comparable to that observed with a neutralizing 
anti-PlGF monoclonal antibody (16D3, Thrombogenics) used at 1,6 nM (Fig. 17). 
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Figure 17: Inhibition of PlGF-induced Flt-1 phosphorilation on 293 cells over-expressing Flt-1 
receptor. The values of densitometry analyses performed using ImageQuant 5.2 software are 
reported. Values of 0 and 100 have been assigned arbitrary, to non-induced and PlGF-induced 
samples. 
 
 
 
In order to evaluate the anti-angiogenic activity of 4-23-5 peptide, it was assayed in 
capillary-like tube formation (CTF) assay. This assay is widely utilized to investigate the 
pro- or anti-angiogenic activity of molecules: primary endothelial cells plated on membrane 
extract (Matrigel) in presence of angiogenic stimuli, such as growth factors like VEGF-A, 
EGFR and FGF, are able to migrate and differentiate generating a network of capillary-like 
structures. PlGF and VEGF-A alone in endothelial basal medium were able to stimulate 
human umbilical vein endothelial cells (HUVECs) inducing a capillary-like network (Fig. 
18.1 And 18.8). Peptides were added with PlGF or VEGF-A at concentration ranging from 
0.16 to 20 M. Selected peptide 4-23-5 were able to suppress completely the PlGF or 
VEGF-A induced CTF at a concentration of 20 M (respectively Fig. 18.2 and 18.9), this 
activity is specific of selected peptides because control peptides 4-23-A (12.8 and 18.10) 
and 21-1-5 (18.4 and 18.11) at 50 M failed to block CTF. Observed inhibition was dose-
dependent, indeed tetrameric 4-23-5 peptide still completely inhibited CTF stimulated by 
both PlGF and VEGF-A at 4.0 M (Fig. 18.5 and 18.12), whereas at 0,8 M (Fig. 18.6 and 
18.13) and 0,16 M (Fig. 18.7 and 18.14), showed respectively strong and partial 
inhibition. These data confirm that selected peptide is able to prevent PlGF and VEGF-A 
activity on endothelial cells, inhibiting angiogenesis-related process such as the formation 
of a capillary-like network. 
 
 
 
 
 
 

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Figure 18: Inhibition of CTF assay 
induced by both PlGF (1-7) and 
VEGF-A at 100 ng/ml (8-14). 
1, 8: PlGF and VEGF-A. 
2, 9: 4-23-5 at 20 M. 
3, 10: 4-23-A at 50 M. 
4, 11: 21-1-5 peptide at 50 M. 
5, 12: 4-23-5 peptide at 4.0 M. 
6, 13: 4-23-5 at 0.8 M. 
7, 14: 4-23-5 at 0.16 M. 
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3.5 In vivo activity of 4-23-5 tetrameric peptide 
 
The anti-angiogenic activity of blocking 4-23-5 peptide was also evaluated in vivo using the 
model of chicken embryo chorioallantoic membrane (CAM) assay [94]. This assay is 
based on the implantation of a gelatin sponge or absorbing beads on the top of the CAM 
during embryonic development. The implanted support is treated with a stimulator of blood 
vessel formation in the absence or presence of an angiogenesis inhibitor. New blood 
vessels that are growing into sponge or converging towards the beads after 72 hours, are 
counted under stereomicroscope. VEGF-A alone exerted a strong angiogenic response 
(494 vessels/embryo) when compared to beads absorbed with vehicle (7.02.2) or 
peptides alone (4.52.5 and 8.05.5 vessels for 4-23-5 and 21-1-5 peptides, respectively). 
The blocking peptide 4-23-5 was able to inhibit the angiogenic response in all tested 
embryos. The number of new vessels was reduced to 33.64.3 (n=6, p˂0.005 vs VEGF-A) 
and to 16.64.9 (n=8, p˂0.0001 vs VEGF-A) with 0.025 and 0.25 nmol (Fig. 19) of peptide, 
respectively. In contrast, no inhibition was elicited by 0.025 nmol of control peptide (n=8, 
45.0±4.7 vessels) whereas a partial inhibition (≥50%) was observed only in 2 out of the 6 
embryos treated with 0.25 nmol of the control peptide (26.8±14.3 vessels, p˂0.005 vs 
VEGF-A, Fig. 19 and 20). 
 
 
 
 
Figure 19: Anti-angiogenic activity of 4-23-5 peptide on CAM assay. Representative pictures of: 1. 
Beads containing VEGF-A alone, 2. PBS, 3. VEGF-A in presence of 0.25 nmol of 4-23-5 peptide, 4. 
VEGF-A in presence of 0.25 nmol of 21-1-5 peptide. 
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Figure 20: graphic representation of CAM assay results. Histogram repots the number of new blood 
vessels converging towards the beads counted under stereomicroscope. The high standard 
deviation presented from 0.25 nmol of control peptide 21-1-5 is due to the partial inhibition showed 
from 2 of the 6 embryos treated. 
 
 
 
 
 
 
 
Recently, Ambati et al have demonstrated the involvement of sFlt-1 in the maintenance of 
cornea avascularity [64]. These data make the cornea the best platform to assay anti-Flt-1 
molecules. Based on these data, 4-23-5 peptide was assayed in cornea neo-
vascularization (CNV) assay. The injection of 20 nmol of 4-23-5 peptide induced a strong 
angiogenic response (Fig. 21) and the effect was dose-dependent. Indeed, injection of 4.0 
nmol or 0.4 nmol still produced clearly visible effects, though to reduced extent. Conversly, 
the injection of 20 nmol of control peptide 21-1-5 was unable to induce CNV. Of utmost 
importance, a single injection of 4-23-5 produced a sustained effect detectable up to 7 
days, confirming the high stability to degradation observed in vitro. 
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Figure 21: Corneal neo-vascularization induced by 4-23-5 peptide. A total of 0.4 (1 and 5), 4.0 (2 and 
6) and 20 (3 and 7) nmol of 4-23-5 peptide and 20 nmol of 21-1-5 control peptide (4 and 8) in DMSO 
were injected in the corneas of Balb/c mice. After 7 days corneas were harvested and flat-mounted. 
New vessels were immunostained (4-8) using anti-mouse CD31 antibodies (green), and anti-mouse-
LYVE-1 antibodies (red). Blood vessels were defined as CD31 positive and Lyve-1 negative. 
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IV. Discussion 
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In the last decade, the concept of angiogenic therapy has been developed as a strategy to 
treat cancer inducing the regression of vessels that provide sustenance to the tumor. 
Recently, it has been re-defined and extended to all pathologies characterized from a 
reduced or excessive angiogenesis. 
Among the several molecular factors involved in the regulation of angiogenesis, VEGF 
family has assumed a central role [7]. 
At the beginning more attention has been conferred to VEGF-A and its specific receptor 
KDR/Flk-1, since this pathway is crucial for endothelial cells activation in angiogenesis 
process and their interaction has been proposed as ideal target for angiogenic therapy 
[81]. However, recent data demonstrate that PlGF and its receptor Flt-1 have a role more 
confined to pathological angiogenesis. 
The deletion of Flt-1 gene in mice causes embryonic lethality due to overgrowth and 
disorganization of blood vessels, not due to a poor vascularization [56], suggesting that 
VEGFR-1 plays a role in the reorganization and stabilization of primitive vascular plexus. 
In contrast, deletion of tyrosine kinase domain of Flt-1 does no cause lethality but it 
generates mice that show a reduced pathological angiogenesis. The same phenotype has 
been described for PlGF knockout mice, indicating that both molecular factors are crucial 
in the induction of angiogenesis in pathological states. Recent data demonstrate that Flt-1 
is not only expressed in ECs but also in monocytes/macrophages, smooth muscle cells 
and also in bone marrow stem/progenitors derived cells, indicating that Flt-1 has also a 
role in stabilization of new blood vessels through the recruitment of SMCs and in the 
recruitment and differentiation of monocyte-macrophage cells which express SMCs and 
ECs mitogens [61]. Moreover, in tumor the inhibition of Flt-1, using an anti-Flt-1 
monoclonal antibody, is able to inhibit tumor growth through the decrease of its 
vascularization. Very recently, similar results have been obtained with an anti-PlGF 
monoclonal antibody [95]. All together these data demonstrate that Flt-1 and its ligand 
PlGF are a target of pathological angiogenesis and their inhibition consistently reduce the 
pathology progression.  
The first anti-angiogenic molecule approved for clinical use has been an humanized anti-
VEGF-A blocking antibody (Avastin, Genetech, Inc.). Moreover human patients treated 
with Avastin have showed undesired effects such as hypertension and thrombosis, due to 
physiological activity of VEGF-A in vessels permeabilization. In contrast, results obtained 
from Fischer et al show that the anti-PlGF monoclonal antibody is able to inhibit tumor 
growth without induce the side effects observed with both anti-VEGFR-2 antibody and 
VEGFR inhibitors, confirming the restricted role of PlGF and Flt-1 to pathological 
angiogenesis. 
Despite the progresses made by biotechnological industry, the using of monoclonal 
antibodies and recombinant proteins is still much expensive mainly because of high costs 
of production. In this contest, small molecules offer numerous advantages: low molecular 
weight often allows to escape recognition immunity system, they can be more easily 
produced, and are generally free of contaminants of biological origin, they offer more 
opportunity for delivery allowing also oral administration and their costs of production are 
lower than that of monoclonal antibodies or recombinant proteins. In this regard, in the last 
two decade a great efforts has been focused both on the realization of combinatorial 
libraries, to increase significantly the number of available molecules, and on the 
development of methods to screen them efficiently and rapidly. Thanks to biotechnology 
progresses, several methods to synthesize and screen in automated way complex libraries 
are available and the only limit is the ability of the investigator to think and design new 
molecular scaffolds, as well as identify new molecular targets. 
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In this work it has been performed the screening of a tetrameric tripeptide library to identify 
new inhibitors of pathological angiogenesis. 
The screening (deconvolution) of a tetrameric tripeptide library, performed with the iterative 
process, has allowed the identification of a peptide named 4-23-5 (Fig. 3). 
The selected peptide is able to inhibit the interaction between Flt-1 receptor and its ligands 
PlGF and VEGF-A, showing an IC50 value of about 10 M estimated by ELISA-competition 
dose–dependent assay (Fig. 9 and 10). The ability to inhibit both interactions is due to 
binding activity of peptide, since it recognizes exclusively Flt-1, while fails to bind KDR/Flk-
1 or soluble factors. The ability of peptide to bind selectively Flt-1 confers it a particular 
interest: it can inhibit the role of Flt-1 in the earliest steps of angiogenesis preventing the 
recruitment of endothelial precursors and moncyte-macrophage and, at the same time, it 
can prevent stabilization of blood vessels by SMCs inducing fragility of the nascent 
vascular network.  
Structural investigation has showed that peptide activity is closely dependent both on the 
aminoacidic sequence, indeed the substitution of a single aminoacid with Alanine causes 
the loss of inhibitory activity (Fig. 11) and on tetrameric structure, indeed this structure 
presents the best inhibition compared with structural analogues (Fig. 12). 
The presence of un-natural aminoacids confers to peptide an utmost resistance to 
protease degradation as compared to other recently reported anti-Flt-1 peptides [96, 97, 
98]. The stability of peptide is crucial for its application in cell-based and in vivo assays. 
The selected peptide is able to inhibit the PlGF-induced phosphorilation of Flt-1 receptor 
indicating that it is able to prevent the first molecular event of signal transduction of PlGF 
through Flt-1 that lead the activation of downstream target gene involved in Flt-1-induced 
response (Fig. 17). 
The inhibition of CTF demonstrates that the inhibition of Flt-1 phosphorilation alone is 
sufficient to inhibit all biological processes that lead the formation of the capillary-like 
network, such as cell proliferation, migration and differentiation. 
Moreover, the inhibition of VEGF-induced CTF together with a sustained inhibition of 
VEGF-induced angiogenesis in CAM assay show that, despite the presence of both 
VEGFRs, the inhibition of the high affinity receptor alone is able to prevent in vivo and in 
vivo angiogenic response to VEGF-A. 
The induction of cornea vascularisation in CNV assay confirms that 4-23-5 peptide is able 
to bind Flt-1 receptor displacing VEGF-A from a pre-formed complex with the receptor. 
Moreover, it does not interfere with Flk-1 receptor because corneal vascularisation is a 
process driven by VEGF-A/Flk-1 interaction. This data demonstrates that also in vivo 
system, the selected 4-23-5 peptide has a high specificity for Flt-1 receptor and do not 
interfere with Flk-1 receptor. Furthermore, at the higher peptide concentration used, the 
formation of new lymphatic vessels is also evident (Fig. 21.3 and 21.7) as showed by anti-
Lyve labelling. This results is consistent with recent data on the ability of VEGF-A to 
stimulate also lymphangiogenesis indicating that for this process the VEGF/Flk-1 
interaction is crucial. 
Although initially in in vitro assay, selected 4-23-5 peptide has showed activity in 
micromolar range (IC50 of 10 M), in all cell-based and in vivo assays it presents an 
inhibitory activity at lower concentration. These results show that selected peptide 
represent a new specific anti-Flt-1 peptide that can be used for molecular therapy 
approach of those pathologies in which angiogenesis represents a crucial event. 
Moreover, anti-Flt-1 antibody is able to reduce atherosclerotic plaques growth and 
suppresses autoimmune arthritic joint destruction through the inhibition of the recruitment 
of myeloid progenitors [61]. Recently, Kaplan et al have demonstrated that Flt-1 marks 
bone-marrow derived haematopoietic progenitor cells and is crucial for their migration to 
tumor-specific pre-metastatic sites, where these cells form a cellular cluster named  ‘pre-
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metastatic niche’ before the arrival of tumor cells [62]. Anti Flt-1 monoclonal antibody is 
able to completely prevent metastasis formation. 
These results indicate that anti-Flt-1 molecules can be also used for the treatment of 
inflammation disorders and to prevent cancer metastasis, other than all pathologies in 
which angiogenesis have a fundamental role. 
Finally, selected peptide represents a new molecular scaffold which can be further 
modified to generate new peptide variants with increased affinity for Flt-1 receptor. 
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V. Matherial and Methods 
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5.1 Synthesis of combinatorial tetrameric tripeptide library and analogues of 4-23-5 
peptide 
For the library synthesis, 30 different blocks were utilized (Table 4), and a theoretical 
number of 27,000 peptides was generated, split in 30 separate pools of 900 peptides 
each. The synthesis was manually carried out on a 300 µmoles scale following standard 
Fmoc methodologies and using PyBOP as coupling agent. A typical acylation/deprotection 
cycle consisted of a 15 minutes coupling step (0.25 M amino acid solutions in situ 
activated with PyBOP and DIEA) and a 10 minutes deprotection step with 30% piperidine 
in DMF. Peptide mixtures were then detached from the corresponding resins by treatment 
with a cleavage cocktail containing TFA-TIS-H2O (95:2.5:2.5, v/v/v) for 2h at RT, then they 
were lyophilized twice, dissolved in DMSO at 5 mg/mL and stored at –80°C until use. 
Assuming an average molecular weight of 2128 amu for the tetrameric tripeptides, 
calculated by summing the average MW of the single building blocks (138.2 amu) 
multiplied by 12, to that of the polylysine scaffold (458 amu), a theoretical 2.6 µM 
concentration for each library component was achieved. No specific characterization were 
performed at this stage given the high complexity of the resulting sub-libraries (900 
components). After the first screening round, the selected sub-library carrying the D-
Glutamic acid (D-Glu, building block  4) on the N-terminus, was prepared following the 
same synthetic approach. A theoretical number of 900 molecules arranged in 30 pools of 
30 peptides each was thus generated. Characterization at this step on selected sub-
libraries was achieved by LC-MS using an LC-MS system equipped with a Surveyor 
HPLC, comprising a quaternary pump and a PDA detector, and the LCQ Deca Ion Trap 
mass spectrometer (ThermoFisher). For the analyses, C18 narrow bore 30x1 mm ID 
Biobasic column (ThermoFisher) equilibrated at 200 µL/min with 5% CH3CN, 0.05% TFA 
were used. Analyses were carried out applying a gradient of CH3CN, 0.05% TFA from 5% 
to 70% over 90 minutes. The mass spectrometer mounted an ESI source maintained at 
320 °C and 4.2 kV. Spectra in positive mode were continuously acquired between 200 and 
2000 amu. Mixtures were detached from the resin as described previously and the 
products were stored in DMSO at 5 mg/mL concentration. The 30 peptides composing the 
sub-library identified in the second screening round and carrying the Cys(Bzl) (building 
block 23) on the known position, were prepared in parallel as single molecules. After 
cleavage from the resin and lyophilisation, the peptides were all characterized by LC-MS 
using a narrow bore 30x1 mm ID Biobasic column equilibrated at 200 µL/min with 5% 
CH3CN, 0.05% TFA. Analyses were carried out applying a gradient of CH3CN, 0.05% TFA 
from 5% to 70% over 13 minutes. Peptides were firstly tested in the competition assay as 
crude products, then the active molecules and those assumed as negative controls were 
purified by semi-preparative RP-HPLC using a 30x1 cm C18 column (Phenomenex, 
Torrance, CA, USA), characterized by LC-MS and re-submitted to the competition assay. 
The active peptides were tested in the cellular assays as acetate salts in order to prevent 
the cytotoxic effects of the TFA present as counterion. To this aim, peptides were 
dissolved in 0.1 M CH3COOH and repeatedly lyophilized. Reagents for solid phase 
synthesis were from Chem-Impex or Novabiochem; solvents were all from LabScan 
(Dublin, Ireland). Reagents for peptide cleavage were from Sigma-Aldrich (Milan, Italy). 
LC-MS systems and columns for LC-MS analysis were from ThermoFisher (Milan,Italy).  
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5.2 Iterative deconvolution of tetrameric tripeptide library. 
At every step of the deconvolution process, peptide pools were tested with a molar excess 
of 1,000-fold (calculated for each single peptide) over PlGF (1.3 x10-10 M). Once identified 
an active pool, a dose-dependent inhibition using 500 - 1,000 - 1,500 and 2,000 fold 
excess was performed to confirm the inhibitory property. The first active pool identified was 
the 4.X.X (X indicated random positions) where “4”   identifies the amino acid D-Glutamic 
(D-Glu, see Table 7). This peptide pool was synthesized in 30 sub-polls, each composed 
of 30 peptides, and submitted to the second screening that allowed the identification of the 
sub-pool  23  (4.23.X),  where  the  number  “23”  identifies  the  amino  acid    L-Cysteine(S-
benzyl) (L-Cys(Bzl), see Table 7). Finally the 30 single peptides composing the 4.23.X 
pool were synthesized and submitted to the final screening. The peptide 4.23.5, where the 
number  “5”  identifies  the amino acid L-Cyclohexylalanine (L-Cha, see Table 7), was the 
unique molecule showing inhibitory activity.  
 
5.3 ELISA-based assays for the screening of library and competition experiments. 
The ELISA based assay for the screening of peptide library and for all competition and 
dose-dependent experiments was performed coating on 96-well plate a recombinant form 
of  Flt-1(VEGFR-1-Fc chimera R&D Systems) at 0.5 mg/mL, 100 ml/well, 16 hrs at room 
temperature. Wells were washed five times with PBS containing 0.004 % Tween-20 (PBT) 
and the plate was then blocked for three hrs at RT with 1 % Bovine Serum Albumin (BSA) 
in PBS, 200 l/well. Wells were washed as above, and a recombinant form of PlGF (R&D 
Systems) at 5 ng/mL in PBS containing 0.1 % BSA, 5 mM EDTA, 0.004 % Tween 20 
(PBET), 100 l/well, was added and incubated for 1 h at 37°C followed by 1 h at RT. Wells 
were washed again and biotinylated anti-human PlGF polyclonal antibody (R&D Systems), 
diluted in PBET at 300 ng/mL, 100 l/well, was added to the wells and incubated for 1 h at 
37°C followed by 1 h at RT. Wells were washed and incubated with a solution containing a 
preformed avidin and biotinylated HRP macromolecular complex (Vectastain elite ABC kit ) 
for 1 hr at RT. After the last wash, 100 l of HRP substrate composed of 1 mg/mL of ortho-
phenylenediamine in 50 mM citrate phosphate buffer pH 5, 0.006 % of H2O2, was added 
and incubated for 40 min in the dark at RT. The reaction was blocked by adding 30 l/well 
of 4 N H2SO4 and the absorbance measured at 490 nm on a microplate reader (Biorad 
BenchMark).  
Peptide pools or single peptides dissolved in DMSO (Sigma) were properly diluted and 
added to the wells pre-mixed with ligand. For dose dependent experiments performed with 
VEGF (R&D Systems), 10 ng/mL of recombinant protein and 300 ng/mL of polyclonal 
antibody anti human VEGF (R&D Systems) were used. For dose-dependent experiments, 
4.-23-5 peptide and control peptides were used at concentration ranging between 1.56 and 
50 mM. 
 
5.4 Inhibitory activity of 4.23.5 sequence- and structure-related analogues. 
The inhibitory properties of Alanine-scan peptides and structurally related analogues in 
both PlGF or VEGF interaction with Flt-1 receptor were investigated using the ELISA-
based assay described above. Peptides were used in competition at 50 M concentration. 
As positive control of inhibition, 4-23-5 was used at 12.5 M whereas as negative control 
was added the same volume of DMSO used to dissolved peptides at the reported 
concentration.  
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5.5 ELISA assays for determination of binding of 4-23-5 peptide to Flt-1 receptors. 
To evaluate the binding of 4-23-5 peptide to Flt-1 receptor, 4-23-5 or control peptides were 
coated at the indicated concentrations, 100 l/well , 16 h at 4°C. Wells were washed five 
times with PBT and the aspecific sites blocked for 3 h at RT with 1 % Bovine Serum 
Albumin (BSA) in PBS, 200 l/well. Wells were washed as above, and recombinant form of 
extracellular domains of human and mouse Flt-1 receptor fused to human Fc in PBET 
were added at the indicated concentrations and incubated for 1 h at 37°C followed by 30 
min at RT. Wells were washed again and a goat anti-human Fc (Jackson 
ImmunoResearch) at 1:1000 was added and incubated 1 h at 37°C and 30 min at RT. 
After the last wash, a donkey anti-goat HPRT (Santa Crutz Biotechnology) at 1:1000 was 
added and incubated 1 h at RT. The HRP substrate and reading of plates was effectuated 
as reported in paragraph 3.3. 
To evaluate the binding of 4-23-5 to VEGFR-2, recombinant human KDR and mouse Flt-1 
extracellular domains fused to human Fc (R&D Systems) were used instead of Flt-1 
receptors. 
 
5.6 Stability assay 
The selected peptide, denoted as 4.23.5 was dissolved in neat DMSO at a 10 mg/mL 
concentration. The sample was then serially diluted in PBS pH 7.3 containing 10% Fetal 
Calf Serum (FCS) in order to obtain 100 µg/ml solutions and incubated at 37 °C for 24 h. 
10 µl aliquots (1.0 µg total peptide) were removed at 0, 4, 8, 12, 16, 20 and 24 h, were 
centrifuged for 5 min at 16000 x g and analyzed by RP-HPLC after discarding the pellet. A 
reference curve was obtained by analyzing, under the same conditions, different amounts 
of the pure compound dissolved in pure DMSO, where it is fully soluble (>100 mg/ml). The 
reference curve was used to exclude effects of sample subtraction by non-specific binding 
to albumin or other serum proteins. The experiment was carried out twice and the data 
were reported as a plot of peak area (%) versus time. 
 
5.7 Inhibition of Flt-1 phosphorylation assay  
HEK-293 over-expressing hFlt-1 cells were grown in Dulbecco’s modified Eagle medium 
(DMEM) supplemented with 10% inactivated fetal bovine serum (Euroclone) and 
antibiotics until 70% confluence, then they were starved overnight at 37°C in serum free 
medium. Medium was removed and cells were preincubated with PBS containg Na3VO4 at 
100µM for 5 minutes to inhibit endogenous phosphatase activity. After cells were 
incubated for 10 min at 37°C with hPlGF alone or with hPlGF and peptide together. Then 
they were washed two times with pre-chilled PBS/Na3VO4 at 100µM anh than lysed in a 
buffer containing 2 mM Tris-HCl at pH 8, 5 mM EDTA, 150 mM NaCl, 1% Triton-X 100, 
10% glycerol, 10 mM zinc acetate, 100µM Na3VO4 and a mixture of protease inhibitors 1x 
for 1 hr at 4°C in agitation. Then the samples were centifugated for 10 min at 12000 x g 
and supernatants were recovered and stored at -80°C. The protein concentration was 
determinated with Bradford method (Bio-Rad assay). To immunoprecipitate Flt-1, 5 µg/ml 
of a goat polyclonal antibody against human Flt-1(Santa Cruz Biotechnology)  was 
incubated with 30 µl of Protein G-Sepharose resin (Amersham Biosciences) overnight at 
4°C. Then the samples were centifugated at 2000 rpm for 5 min and resins were incubated 
with 1 mg of proteic extract overnight at 4°C. After the removal of supernatants, resins 
were washed twice with lysis buffer, twice with lysis buffer without detergent and finally 
with Tris-buffered saline. The pellets of resin were treated with 20 µl of Lemly buffer 1x in 
riducent condition, boiled at 100°C for 5 min and supernatants were loaded on a reducing 
8.5% SDS-PAGE. Proteins were detected by western blottind as described above. 
To detect the phosphorilation level of Flt-1, the filter was incubated primary with mouse 
monoclonal antibody against phospho-tyrosine (Sigma) diluited 1:1,000 in BSA 3%/ Tris-
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buffered saline (blocking buffer), 1 hr at room temperature and after with an anti-mouse 
HRP-conjugated antibody (Pierce) diluited 1:10,000 in blocking buffer, as the secondary 
antibody. The same filter was stripped with -mercaptoethanol 100 mM, TRIS-Cl 62.5 mM 
pH 6.7 and SDS 2% for 30 min at 50°C. Then the filter was incubated with mouse 
monoclonal antibody against VEGFR-1 (Sigma) diluited 1:500 in no fat milk 5% in Tris-
buffered saline, 1hr at room temperature followed by incubation with the secondary 
antibody (Pierce) diluited 1:10,000. 
Densitometry analysis to evaluate the degree of Flt-1 phosphorilation was performed using 
ImageQuant 5.2 software (Amersham Biosciences). 
 
5.8 Capillary-like tube formation assays 
A 48 well plate was coated with MatrigelTM (BD Biosciences) diluited 1:1 in endothelial 
basal medium(EBM)-2 medium (Cambrex) (110µl/well) and incubated at 37°C for 30 min. 
HUVECs (Cambrex) (75000 cells) were seeded in 500 µl of EBM-2 medium in the 
presence of both PlGF-1 or VEGF (100 ng/ml) and peptides at a concentration ranging 
from 4 to 0.16 µM. Endothelial growth medium (EGM)-2 (Cambrex) and EBM-2 medium 
were used respectively as positive and negative control. After 6 hours of incubation, 
capillary-like tube formation was examinated under an inverted phase microscope. Cells 
were fixed with PBS containing 0.2% glutaraldehyde, 1% paraformaldheyde and 
photographed. To confirm the specificity of selected peptides, an unrelated tetrameric 
peptides was used at a concentration of 4 µM. The assays were performed in triplicate. 
The same protocol was made to test the organic molecules, with the difference that they 
were added in a concentration range from 2 to 20 M 
 
5.9 Chicken embryo chorioallantoic membrane (CAM) assay  
Alginate beads (5 l) containing vehicle or 150 ng/embryo of VEGF165 with or without 
peptides (0.25 and 0.025 nmoles/embryo) were prepared as described [87] and placed on 
top of the CAM of fertilized White Leghorn chicken eggs at day 11 of incubation (6-8 eggs 
per experimental group). After 72 hours, new blood vessels converging towards the 
implant were counted by two observers in a double-blind fashion under a 
stereomicroscope (STEMI-SR, x2/0.12; Zeiss). 
 
5.10 Cornea neo-vascularization 
Single injections of 0.4, 4 or 20 nmol of peptide 4-23-5 in DMSO were carried out (33 
gauge needle) in the corneas of Balb/c mice (n=3 each group). Eyes were harvested 7 
days after injection, corneas were gently isolated and immunohistochemical staining for 
vascular endothelial cells was performed. Corneas were fixed in 100% acetone for 20 
minutes, washed with PBS – 0.05% Tween 20 for 10 minutes four consecutive times, and 
blocked with 3% BSA in PBS for 48 hours. The corneas were then incubated with FITC-
coupled monoclonal anti-mouse CD31 antibody (Pharmingen) at 3:1000 and rabbit anti-
mouse LYVE-1 antibody (Abcam) at 3:1000 in 3% BSA PBS solution at 4 °C for 48 h. The 
corneas were washed as previously described and incubated in Cy3 conjugated donkey 
anti-rabbit at 3:1000 in 3% BSA PBS solution for 2 h after which they were washed and 
mounted with an antifading agent (Vectashield). The corneal flat mounts were visualized 
with a fluorescent microscope (Nikon Eclipse TE2000-E). Blood vessels were defined as 
CD31 positive and LYVE-1 negative. 
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Identification of inhibitors of PlGF/ Flt-1 interaction by the screening of peptide 
compounds libraries. 
D. Marasco1‡,  S. Ponticelli2‡, A. Saporito1, V. Tarallo, E Benedetti1, C. Pedone, J.M. 
Stassen3, S. De Falco2 and M. Ruvo1.  
 
1Istituto di Biostrutture e Bioimmagini, Sezione Biostrutture, Napoli-Italy; 2Istituto di Genetica e 
Biofisica “Adriano B. Traverso” del CNR, Napoli-Italy, 3Thromb-X N.V., Leuven, Belgium. 
‡ These authors contributed equally to this work. 
 
Blood vessel formation largely contributes to the pathogenesis of numerous diseases, 
including ischemia and cancer [1-2]. In this regard therapeutic strategies aim to stimulate 
vascular growth in ischemic tissues and suppress their formation in pathologies like in 
tumour and diabetic retinopathy. Placental growth factor (PlGF), an homolog of vascular 
endothelial growth factor (VEGF), (42% amino acid sequence identity), stimulates 
angiogenesis and collateral growth in ischemic heart and limb. Whereas VEGF exerts it 
biological function through the binding to both VEGF receptor-1 (VEGFR-1or Flt1) and 
VEGFR-2 (or KDR) PlGF binds specifically to Flt1. The complex PlGF/Flt1 constitutes a 
potential candidate for therapeutic modulation of angiogenesis and inflammation [3].  
The binding between PlGF and Flt-1 has multipunctual features [4] and potential 
antagonist must have a sufficient molecular surface to spatially distant contact points. We 
have used an ELISA-like screening assay to select antagonists of PlGF/Flt-1 complex from 
a large random library of tetrameric unnatural peptides (complexity: 330=27.000 molecules) 
identifying two active molecules with an about 10  M IC50. The relative stability of 
identified peptides were assessed in human serum and their inhibitory properties were 
tested in a capillary-like tube formation assay performed with Human Umbilical Vein 
Endothelial Cells (HUVEC). 
References 
1. Bussolino et al. TIBS, 1997, 22, 251-256. 
2. Iyer, S., et al., J. Biol. Chem. 2001, 276(15), 12153-12161 
3. Carmeliet P, et al. Nat Med 2001, 7(5):575-83  
4. Davis-Smyth T. et al J. Biol. Chem. 1998, 273(6), 3216-3222 
 
 
New inhibitors of pathological angiogenesis 
 
64 
 
Identification of Cripto inhibitors to direct cell fate specification in ES cells 
 
E. Lonardo, S. Ponticelli, D. Marasco*, A. Saporito*, M. Ruvo*, S. De Falco, G. Minchiotti 
 
Institute of Genetics and Biophysics "A. Buzzati-Traverso", CNR, Via P. Castellino 111, 
80131, Naples, Italy. * Institute of Biostructure and Bioimaging, CNR, Via Mezzocannone 
16, 80134, Naples, Italy. 
 
 
 Cripto is a cystein-reach protein anchored to the cell membrane through a glycosyl-
phosphatidylinositol (GPI)-linkage, and it is the founding member of the EGF-CFC family. 
Cripto is expressed both in the Embryonic Stem (ES) cells and during the early phases of 
embryo development while, in the adult, it is reactivated in a wide range of epithelial 
cancers. Recent studies, revealed that cripto is a key molecule required for both induction 
of cardiomyocyte differentiation and repression of neural differentiation in ES cells. 
Recently, we have show that in vitro differentiation of Cripto-/- (ES) cells results in 
increased dopaminergic differentiation and that, upon transplantation into Parkinsonian 
rats, they result in behavioural and anatomical recovery with no tumor formation (Parish et 
al, 2005). Indeed, these results strengthen the importance of identifying Cripto inhibitor 
molecules as a powerful tool to decode the molecular mechanisms of Cripto function both 
in stem cell differentiation and tumorigenesis. We are thus exploiting a novel experimental 
approach based on the use of combinatorial chemistry combined to ES cell differentiation, 
to identify new molecules able to inhibit Cripto signaling by interfering with Cripto binding 
to the receptor as new tools to direct neuronal fate specification from mouse ES cells. By 
using an in vitro ELISA-based technology, we have screened a tetrameric tripeptide library 
and identified peptides that are able to inhibit Cripto/ALk4 receptor interaction; selected 
peptides showing the highest inhibitory effects in the ELISA assay are currently tested in 
the ES cell differentiation assay. The availablity of molecule(s) which antogonize Cripto 
activity, may represent a powerful tool to dissect the functional role of Cripto in ES cells 
differentiation.  
 
 
Parish CL, Parisi S, Lago CT, Persico MG, Arenas E, Minchiotti G. Cripto  as a target for 
improving embryonic stem cell-based therapy in Parkinson’s disease. Stem Cells. 2005; 
23:471-476. 
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Chemical Synthesis of Mouse Cripto CFC Variants
Daniela Marasco,1 Angela Saporito,1 Salvatore Ponticelli,2 Angela Chambery,3 Sandro De Falco,2 Carlo Pedone,1
Gabriella Minchiotti,2* and Menotti Ruvo1*
1Istituto di Biostrutture e Bioimmagini del CNR, Sezione Biostrutture, Napoli, Italy
2Istituto di Genetica e Biofisica “Adriano B. Traverso” del CNR, Napoli, Italy
3Facolta` di Scienze MMFFNN, Seconda Universita` di Napoli, Caserta, Italy
ABSTRACT We report for the first time the
chemical synthesis of refoldedCFCdomain ofmouse
Cripto (mCFC) and of two variants bearing muta-
tions on residues W107 and H104 involved in Alk4
binding. The domains undergo spontaneous and
quantitative refolding in about 4 h, yet with very
different kinetics. Disulfide linkages have been as-
sessed by enzyme digestion and mass spectrometry
analysis of resulting fragments, and the first experi-
mental studies on structural organization have been
conducted by circular dichroism spectroscopy un-
der different pH conditions. Upon refolding, the
domains considerably change their conformations,
although they do not assume canonical structures,
and become highly resistant to enzyme degradation.
A comparative study of receptor binding shows that
the CFC domain can bind Alk4 and confirms the
importance of W107 and H104 for receptor recogni-
tion. Proteins 2006;64:779–788. © 2006 Wiley-Liss, Inc.
Key words: peptide synthesis; CD spectroscopy; do-
main refolding; enzymedigestion; recep-
tor binding
INTRODUCTION
hCripto is the founding member of a family of soluble
and cell-bound growth factors known as EGF-CFC [re-
viewed in Refs. 1–5] distinguished by the presence of an
N-terminal signal peptide, two distinct CRDs, and a
C-terminal hydrophobic region involved in cell-surface
attachment by a posttranslational GPI modification.6 The
characteristic CRDs, known as EGF-like and CFC do-
mains (from the first members Cripto, FRL1 and Cryptic),
both span about 40 residues with three disulfide bridges
each, which, presumably, besides a possible functional
modularity, also confer them a structural independence.
EGF-CFC proteins range from 171 to 223 amino acids in
length and share an overall sequence similarity estimated
between 22–32%. In converse, isolated CRD domains are
considerably more conserved among all variants, showing
a 60–70% (EGF) and 35–48% sequence homology (CFC), a
feature suggestive of highly conserved functionalities. The
sequence of mouse and human Cripto CFC are nearly
identical, sharing about 80% of sequence identity (Fig. 1).
Previous investigations conducted by using synthetic
polypeptides and supported by molecular modeling have
suggested that EGF-like domains display the same disul-
fide arrangement as canonical EGFs, namely, C1OC3,
C2OC4, and C5OC6,7 so they reasonably exhibit a more
compact tertiary structure compared with classical EGF
motifs, because of a shorter B loop and the lack of the A
loop. According to these peculiar features, the EGF-CFC
proteins are unable to directly interact with any EGF
receptor.8 CFC domains, however, have been so far
uniquely found in EGF-CFC proteins: they do not carry
any posttranslational modification, and experimental data
regarding 3D structural organization have so far not been
reported. The disulfide bridges arrangement, initially
thought to be equivalent to that of the EGF, has been
recently elucidated by mass spectrometry analysis of
peptide fragments derived by proteolytic degradation and
it has actually resulted in a C1OC4, C2OC6, C3OC5
pattern.9 In the same report, a study by disulfide pattern
search and comparative modeling has also suggested that
the CFC domain of human Cripto could be structurally
homologous to the von Willebrand factor type C-like
domain, VWFC (the region encompassing the first six
cysteines) and that a 3D structural model can be derived
by using as a template the NMR structure of PMP-C, a
serine protease inhibitor having the same pattern of
disulfide connections.9 By using both the 3D structural
model derived for the CFC and a model derived by the
NMR structure of the murine EGF, a 3D representation of
the whole protein has been proposed that is consistent
with data obtained from functional studies.9–12 Previous
studies, performed by homology modeling10 proposed a
Abbreviations: hCripto, human Cripto; EGF, epidermal growth
factor; CRD, cysteine-rich domain; 3D, three-dimensional; NMR,
nuclear magnetic resonance; TGF, transforming growth factor; CHT,
chymotrypsin; PDA, photo diode array; CD, circular dichroism; ECD,
extracellular domain; RT, room temperature; HBTU, 1-H-benzotriazo-
lium, 1-[bis(dimethylamino)methylene]-hexafluorophosphate(1-),3-
oxide; HOBt, N-hydroxybenzotriazole; DIEA, diisopropylethylamine;
Fmoc, fluorenylmetoxycarbonyl; TFA, trifluoroacetic acid; TIS, tri-
isopropylsilane; TPCK, 1-chloro-3-tosylamido-4-phenyl-2-butanone;
TLCK, 1-chloro-3-tosylamido-7-amino-2-heptanone; GPI, glycosylphos-
phatidylinosytol; RP-HPLC, reversed phase-high performance liquid
chromatography.
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model of Cripto having a !-trefoil structure similar to that
of FGF. This model, built assuming for the CFC an
EGF-like disulfide structure, although supporting most of
the observations derived by site mutagenesis, seems to be
incorrect. Nevertheless, the true structure of the whole
Cripto protein, as well as of the single domains, are still far
to be elucidated, possibly because of the difficulty in
obtaining sufficient amounts of refolded Cripto protein.
Different roles of Cripto have created considerable inter-
ests; indeed, Cripto is a key regulator of early embryo
development,13,14 of embryonic stem cell differentiation,15
and, in adults, of mammary gland development.16 More-
over, Cripto is now recognized as an important modulator
of angiogenesis, as very recently demonstrated by Bianco
and coworkers.17 The increasing interest in the EGF-CFC
proteins and in particular in human Cripto is, however,
mainly elicited by their strong implication in the growth
and maintenance of a large variety of tumors.2,8,18,19
Indeed, Cripto is overexpressed in a wide range of epithe-
lial cancers, including breast, colon, and stomach carcino-
mas, whereas its expression is reduced or even absent in
normal tissues.8,18,19 Furthermore, either exposure of
mammary cells to Cripto protein or its hyperproduction in
vivo in transgenic mice16,20–23 has provided direct evi-
dence of cell transformation and mammary gland carci-
noma development capacities. Recent reports18,24,25 have
demonstrated the successful use of anti-Cripto monoclonal
antibodies as effective anticancer agents in several xeno-
graft models, thus further classifying Cripto both as an
established player of deregulated cell growth and as an
important point of therapeutic intervention for treating
several widespread cancers.18,24 Cripto enters several
distinct pathways that lead to enhanced cell proliferation,
survival, and motility2,18,26,27 and it is conceivable that all
can validly concur to promote tumor formation and progres-
sion.4 Among the others, regulation of a serin/threonin
kinase activin receptor complex (ActRIB/ActRIIB),28 the
activation of MAPK/akt proliferative,29 and the p38/JNK
antiapoptotic18 pathways have been convincingly demon-
strated. Regulation of activin receptors seems to occur
through binding to both receptors and ligands, notably
Nodal30,31 and Activin24,25; however, the relative contribu-
tion of the interactions, mediated by single Cripto CRD, to
downstream activation is still largely debated. It has been
shown that Cripto binds to nodal through the EGF-like
domain, where the fucose modification has an important
role,12,31 while it anchors to ActRIB (Alk4), as well as to
activin B, via the CFC.9,11,18,24 In this respect, an intrigu-
ing model has been proposed in which the CFC-mediated
binding of Cripto to Alk4 and/or to activin B2,24,25,27 might
eventually induce the oncosuppressive activity of ac-
tivin32–36 and, possibly, of other TGF! proteins.37 These
studies have suggested a prominent role for the single
CRDs in Cripto-mediated carcinogenesis and now prompt
the expenditure of major efforts for the comprehension of
their 3D features, as well as for the identification of
effective antagonists. Most studies performed on the CFC
domain have been focused on the loop comprised between
Cys115 and Cys128 (mouse numbering, Fig. 1) and in-
volved His104, Trp107, and Leu122, whose substitution
with alanine or glycine10,11,13,24 produces inactive vari-
ants.
In the present work, we have focused our attention on
the CFC domain of mouse Cripto. The domain has been
produced by stepwise solid phase synthesis, along with
variants bearing mutation on H104 and W107 (H120 and
W123 according to the human numbering) that have been
described as crucial residues for Alk4 receptor recognition.
Both variants have been purified and refolded, achieving
the correct disulfide bridges, and comparatively analyzed
by CD spectroscopy under different pH conditions, thus
obtaining, for the first time to our knowledge, experimen-
tal insights on the structural arrangements of this new
class of protein domains. Furthermore, the binding proper-
ties of both wild type and mutated CFC domains to Alk4
receptor have been determined by using an ELISA-based
assay. Our results demonstrate that the CFC domain
alone can directly bind Alk4 in the absence of additional
ligands and, furthermore, confirm a role of H104/W107 in
Cripto/Alk4 interaction.
EXPERIMENTAL PROCEDURES
Materials and Instrumentations
Protected N"-Fmoc-amino acid derivatives, coupling re-
agents, and Rink amide MBHA resin were purchased from
Calbiochem-Novabiochem (Laufelfingen, Switzerland).
DIEA was from Applied Biosystem (Foster City, CA). All
other chemicals were commercially available from Sigma-
Aldrich, Fluka (Bucks, Switzerland), or LabScan (Stillor-
gan, Dublin, Ireland) and used as received unless other-
wise stated. Sequencing-grade trypsin and "CHT were
from Sigma-Aldrich (Milano, Italy). Other reagents and
chemicals suppliers are indicated in the Methods section.
Fig. 1. Alignment of primary sequences of mouse and human Cripto CFC domains. The two domains have
been prepared as N-terminal acetylated and C-terminal amidated derivatives. Disulfide bridges are indicated.
The asterisk indicates the conserved residues, whereas a colon indicates amino acids with similar properties.
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Solid-phase peptide synthesis was performed on a fully
automated peptide synthesizer, Applied Biosystems model
433A. Analytical RP-HPLC was performed on a Shimadzu
10A-LC using a Phenomenex C18 column (Torrance, CA),
4.6# 250 mm 5 $m. Preparative RP-HPLCwas performed
on a Shimadzu LC-8A, equipped with an SPD-M10 AV
detector on a Phenomenex COMBI C18 column (5# 2.2 cm
ID; 10 $m). LC-MS analysis was performed on an LCQ
DECA XP Ion Trap mass spectrometer (ThermoElectron,
Milan, Italy) equipped with an OPTONESI source, operat-
ing at 4.2-kV needle voltage and 320°C, and with a
complete SurveyorHPLC system, comprising anMS pump,
an autosampler, and a PDA. Narrow bore 50 # 2 mm C18
BioBasic LC-MS columns from ThermoElectron were used
for these analyses. CD spectra were obtained at room
temperature on a Jasco J-715 dichrograph, calibrated at
290 nm with an aqueous solution of D(%)-10-camphor
sulphonic acid,38 using 0.1-mm quartz cuvettes. UV-Vis
spectra were performed by using a UV-Vis Jasco (Easton,
MD) model 440 spectrophotometer with a path length of 1
cm. The ECD of Alk4 fused to Fc (Alk4-Fc) was from R&D
Systems; reagents for ELISA assays were all from Sigma-
Aldrich (Milano, Italy).
METHODS
Synthesis of CFC Domains
The mouse CFC domain 96-134 (mCFC) and the mu-
tated variants CFC 96-134H104A and CFC 96-134W107A
(mCFC-H104A and mCFC-W107A), all as acetylated and
amidated derivatives, were obtained by stepwise solid
phase synthesis following standard Fmoc/HBTU method-
ologies39 on a 100 $mol scale (RINK amide resin, 1.1
mmol/g). A 10-fold excess of amino acids, preactivated with
HBTU/HOBt/DIEA (1:1:2), was used throughout the syn-
thesis. Coupling and deprotection times were kept at 25
and 15 min, respectively. Standard side-chain protection
groups for Fmoc chemistry were used for all residues; the
six cysteines, introduced as trityl (Trt) derivatives, pro-
duced after cleavage as many free thiol groups.
After resin assembling, polypeptides were removed from
the solid support by treatment with a TFA/H2O/TIS (94:
3:3 v/v/v) mixture (RT, 4 h, 1.0 mL mixture/100 mg resin),
precipitated in cold ethyl ether (Et2O) and lyophilized.
Crude products were analyzed by RP-HPLC using a gradi-
ent from 20 to 45% B over 50 min at 1.0 mL/min flow rate,
using a Jupiter 250 # 4.6 mm ID C18 column (solvent A
was H2O, 0.08% TFA; solvent B was CH3CN, 0.05% TFA).
Crude polypeptides were fully reduced in 100 mM DTT/
100 mM TRIS, pH 7.0 at 37°C for 2 h and purified by
reversed-phase HPLC using a Phenomenex COMBI C18
column 5# 2.1 cm ID and applying a gradient of B from 20
to 45% over 30 min (flow rate was 20 mL/min). Purified
polypeptides were then characterized by analytical RP-
HPLC and ESI-MS mass spectrometry and lyophilized.
For refolding, the polypeptides were again reduced in 100
mM DTT for 30 min at RT, then the reducing agent was
removed by rapid reverse-phase adsorption/desorption,
using 95% CH3CN, 0.05% TFA to elute the peptides. After
CH3CN rapid evaporation under reduced pressure, the
residual solutions were diluted up to a 0.2 mg/mL final
concentration (about 44 $M) using either 100 mM carbon-
ate buffer, pH 8.5 or 100 mM TRIS, 0.5 mM EDTA, 20%
DMSO, pH 8.5 (refolding buffer40). This process was
required to trigger the refolding on purified, completely
reduced materials. The refolding solutions were left at RT
for 16 h and the refolding progression was monitored by
using LC-MS analysis, following retention time shifts and
MW changes. A gradient from 20 to 35% B over 50 min at
0.2 mL/min flow rate was applied to elute the polypeptides.
The spectrometer source was kept at 4.2 kV and 320°C;
sheath and auxiliary gas were fixed at 70 and 15 unit,
respectively. Other ESI source parameters were optimized
by automatic tuning using diluted solutions of the ana-
lytes. Refolded molecules were purified by preparative
RP-HPLC, using a gradient from 20 to 45% B over 12 min
with a flow rate of 20 mL/min. The purest fractions were
collected, lyophilized, and extensively characterized by
using RP-HPLC and ESI-MS mass spectrometry for exact
mass determination. MS analysis was performed by infus-
ing diluted solutions (10 $g/mL) of the purified molecules
at 5 $L/min, and keeping the source at 180°C. Other
parameters were left unchanged.
Analysis of Refolding Progression
One hundred-microgram aliquots of mCFC, mCFC-
H104A, and mCFC-W107A in 500 $L refolding solutions,
were placed in the LC-MS autosampler, thermostated at
20°C. A BioBasic 50 # 2 mm ID RP18 column was
equilibrated at 0.2 mL/min (column temperature was kept
at 25°C) with 20% CH3CN, 0.05% TFA (solvent B) and
5-$L aliquots (1 $g) were automatically injected and
analyzed using a gradient from 20 to 35% B over 50 min
after 0, 90, 180, 270, 360, 450, 540, and 630 min, respec-
tively. PDA data were collected between 200–320 nm
(1-nm bandwidth), whereas mass spectra were continu-
ously acquired between 400–2,000 amu (normal mode)
and 1,200–3,200 amu (high mode). The source was kept at
320°C, the needle voltage at 4.2 kV, and the sheath and
auxiliary gas at 70 and 15 unit, respectively.
Estimation of Free Thiols
In a second experiment, 20 $g of reduced mCFC, mCFC-
H104A, and mCFC-W107A were dissolved in 0.1 mL of
refolding buffer. From each solution, 20-$L aliquots were
taken out after 0, 30, 60, 240, and 600 min and treated
with 1 $L of a 200mM 4-vinylpyridine41 solution in DMSO
for 30 min at 45°C, then 1% TFA was added (10 $L) to
quench the reaction. Five-microliter aliquots (1 $g) were
analyzed by using LC-MS as described for the refolding
experiment.
Assessment of Disulfide Bridges
Disulfides linkages were assessed on mCFC and mCFC-
W107A by treatment of polypeptides with TPCK-treated
trypsin followed by TLCK-treated "CHT and mass analy-
sis of resulting fragments. To this aim, 100-$g polypeptide
aliquots were treated overnight (ca. 16 h) with trypsin at
1:100 enzyme/substrate ratio (w/w), in 100 $L of buffer, 50
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mM TRIS, 20 mM CaCl2, pH 8.5, at 37°C. Sample aliquots
were removed, treated with 50 mM DTT and analyzed by
using MALDI-TOF MS (1 $L treated with C18 ZIP-TIP,
Waters). After the MALDI-TOF MS analysis, 1:100 "CHT
(w/w) was added to the remaining samples and the reac-
tion incubated for 3 h at 25°C and for further 2 h at 37°C. A
2-$L aliquot (2 $g) was removed, diluted with 18 $L of 2%
solvent B in solvent A (v/v), and analyzed (10 $L, 1 $g) by
using LC-MS on the BioBasic column, applying a gradient
from 2 to 55% CH3CN, 0.05% TFA over 160 min. Detection
was achieved, as described, by PDA and mass analysis. In
this last case, data dependent analysis was also conducted,
carrying a fragmentation of all precursor ions with a fixed
40% energy value.
CD Analysis
CD spectra of refolded polypeptides were recorded on
solutions with Cpep & 1.0 # 10
'3 M, calculated by UV
measurements using a molar extinction coefficient at 280
nm of 5,500 M'1cm'1 for mCFC-W107A and 11,000
M'1cm'1 for wild type mCFC and mCFC-H104A. Three
separate 1.0 # 10'3 M solutions for each domain were
prepared at pH 7.0 (10 mM phosphate buffer), pH 5.0 (10
mM acetate buffer), and pH 3.0 (10 mM citrate buffer).
Spectra were recorded using a 0.1-mm path length quartz
cuvette. Data were collected at 0.2-nm intervals with a
20-nm min'1 scan speed, a 2-nm bandwidth, and a 16-s
response, from 260 to 190 nm. Three spectra for each
sample were recorded, averaged, and transformed in mo-
lar ellipticity/residue [(].
Binding Assays With Alk4
To determine the binding activity of the CFC domains to
the Alk4 receptor, the ECD of Alk4-Fc recombinant pro-
tein was adsorbed to 96-well microtiter plates (20 ng/well)
and incubated overnight at RT. After blocking the plates in
2% milk, the CFC peptides (wild type, W107A, or H104A)
were added at concentrations ranging from 50 to 2,000
ng/mL (11–454 nM, assuming an average MW of 4,400
amu for all domains) and incubated for 1 h at 37°C
followed by 1 h at RT. Anti-mouse Cripto rabbit polyclonal
antibodies,10 immunopurified on a Sepharose-CFC pep-
tide column, were then added to the plates at a concentra-
tion of 6 $g/mL and incubated for 1 h at 37°C followed by
1 h at RT. Dilutions (1:10,000) of anti-rabbit immunoglobu-
lin G conjugated to horseradish peroxidase (Santa Cruz
Biotechnology, Santa Cruz, CA) were added to the plates
and further incubated for 1 h at RT. Finally, the plates
were developed with o-phenylenediamine peroxidase sub-
strate (Sigma-Aldrich) and the absorbance was read at 490
nm on a microplate reader (Biorad BenchMark). OD
values were reported versus peptide concentration. Data
represent the means of three independent experiments.
RESULTS AND DISCUSSION
The sequence of mouse Cripto CFC domain was chosen
on the basis of the reported literature (Fig. 1). In a first
attempt, synthesis and refolding of segment 99-133 10 was
unsuccessful, as no refolded product was obtained (data
not shown). The sequence was therefore extended on the
N-terminal side, up to residue K96, whereas the D134
residue was added on the C-terminus. Polypeptides were
assembled by stepwise solid phase synthesis on RINK
AMIDE resin and removed from the solid support by
treatment with a TFA-scavengers solution. After lyophili-
zation and extensive reduction with DTT, the crude prod-
ucts were analyzed by using RP-HPLC observing an
average 70% purity for all products (not shown). Reduction
greatly improved the chromatographic profile of crude
polypeptides, pointing out that highly reactive cysteine
thiols were present even at very acidic pH. DTT-reduced
products were purified by preparative RP-HPLC and again
characterized by analytical RP-HPLC and ESI-MS mass
spectrometry. Products were highly homogeneous (not
shown) and MWs were in very good agreement with
calculated values; mCFCExp/Calcd: 4,475.61) 0.05/4,475.30
amu;mCFC-W107AExp/Calcd: 4,360.16) 0.11/4,360.30 amu;
mCFC-H104AExp/Calcd: 4,409.16 ) 0.15/4,409.28 amu (av-
erage MW). Aliquots were refolded in diluted solutions
using DMSO as slightly oxidizing agent and monitoring
the reaction by LC-MS. The polypeptides underwent spon-
taneous and quantitative conversion [Fig. 2(A–C)], show-
ing, on RP-HPLC analysis, single, sharp peaks with consid-
erable shorter retention times compared with the starting
material (under the reported analysis conditions, about 8
min for the wild type domain, about 7 min for the
mCFC-H104A, and about 5 min for the mCFC-W107A).
Furthermore, a mass loss of 6 amu, suggestive of three
disulfide bridge formation, wasmeasured by using ESI-MS
analysis on all refolded domains. As shown in Figure
2(A–C), the mCFC-W107A polypeptide exhibited the high-
est reactivity compared with the wild type CFC and the
H104A variant, as, once dissolved in the DMSO-containing
buffer (actually, after about 5 min, considering the time
that the autosampler needs to perform the first injection),
new small peaks with shorter and longer retention times
were detected [Fig. 2(B), chromatogram t& 0]. Conversely,
the H104A mutant appeared rather unreactive, being
highly refractory to transformation until about 180 min.
Small amounts of refolded H104A mutant [Fig. 2(C),
arrow, Rt: 33.4 min] were detectable only after 270 min,
then a rapid conversion occurred in the following 90 min,
producingmore than 50% of refolded product, as estimated
by area integration. In the following 90 min (from 360 to
450 min), almost 90% of the final product was formed. In
the same time interval, both wild type mCFC and mCFC-
W107A were completely refolded, yet with very different
kinetics. After the apparent initial inertness, the wild type
domain rapidly evolved in the first 90 min, converting for
about 30% to the refolded form. After 180 min, about 70%
was refolded, whereas the remaining 30% was nearly
present as a single intermediate species (Rt & 31.4 min),
with two disulfide bridges [Fig. 2(A), arrow; MW: 4,471.51
amu]. At the same time, the W107A mutant was formed
for about 60%, but the remaining 40% was spread on a
very large number of intermediates containing one or two
disulfide bridges. After 270 min, both wild type and
W107A domains were almost fully refolded, compared
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with the H104A mutant that required some 450 min to
completely convert to the final product. Interestingly, the
rate of transformation for all variants rapidly increased
after the appearance of a small, slightly hydrophobic peak,
indicated by a downward arrow (s) in Figure 2(A–C), at
39.0 min for the wild type mCFC, at 31.0 min for the
mCFC-W107A, and at 42.8 min for the mCFC-H104A,
respectively. These peaks, corresponding to cyclic polypep-
tides with a single disulfide bridge (as determined by
on-line mass analysis), are likely highly reactive precur-
sors that promote the subsequent fast transformation into
refolded products.
All refolded polypeptides showed sharp, very clean
peaks, with the expectedMW and UV spectra in the region
240–320 nm (determined by on-line PDA analysis, not
shown). The apparent higher hydrophilicity of refolded
domains, as compared with the starting material, was
considered as a first indication of correct domain assem-
bling, because, as expected for globular proteins, most
hydrophobic residues remain buried inside the protein
body upon refolding (assuming they are in a pseudo-native
state under the HPLC analysis conditions). Furthermore,
the molecular surface of a globular domain available for
interaction with the column stationary phase is greatly
reduced comparedwith large, randomly organized polypep-
tides. After reverse-phase purification, the polypeptides
were again characterized by using RP-HPLC analysis
[observing*95% RP-HPLC purities, Fig. 3(A–C)] and MW
determination by ESI-Ion Trap MS. MWs were 4,353.90)
0.14 (mutant W107A), 4,403.20 ) 0.15 (mutant H104A),
and 4,469.22 ) 0.22 amu (wild type), respectively, in very
good agreement with the theoretical values of 4,354.16,
4,403.24, and 4,469.30 amu [see Fig. 3(D–F)]. By these
analyses, we can conclude that refolding is kinetically and
thermodynamically strongly influenced by the point muta-
tions. In particular, substitution of W107 with an alanine
does not greatly affect the kinetics, but has a strong effect
on relative stability of refolding intermediates that prob-
ably rapidly interchange with each other. However, ex-
change of H104 with an alanine not only involves a
reduction of intermediates stability, but also has a pro-
found influence on refolding kinetics, producing a marked
decrease in conversion rate.
Estimation of Free Thiols
To rule out the presence of partially refolded products or
the occurrence of reshuffling reactions, an estimation of
residual free thiols was performed on the refolded domains.
To this aim, reduced polypeptides were refolded as described
and small aliquots were removed after 0, 30, 60, 240, and 600
min and subjected to extensive thiol alkylation using 4-vi-
nylpyridine.41 Analysis by LC-MS, under the same condi-
tions reported for the refolding monitoring, showed that the
fully reduced products took up six 4-VP (MW increase of
105.2 # 6 & 630.8 amu), whereas the refolded polypeptides
wereunaffected by the alkylating reagent.Refolding interme-
diates carrying only one or two disulfide bridges were also
easily identified in the reaction mixtures, up to 240 min
reaction time, as tetra- and di-VP adducts having MW
increases of 420.6 and 210.3 amu, respectively. In Figure 4 is
reported the LC-MS analysis of samples taken after 0, 60,
and 240 min referred to the W107A mutant. The absence of
vinyl-pyridine adducts indicated that no residual free thiols
were present in the refolded domains and that they did not
undergo thiol exchange reactions, further suggesting a high
structural stability.
Disulfide Bridges Assessment
To assess the correctness of disulfide bridges, two of the
three domains, mCFC and mCFC-W107A, were subjected
to proteolysis with a combination of trypsin and "CHT.
Single enzyme treatments had provided single, disulfide-
linked molecules, devoid of linkages information. Long
incubation times were required to obtain diagnostic frag-
ments, as both domains exhibited a marked resistance to
enzyme proteolysis. After the first enzyme addition (1:100
enzyme/substrate ratio), reactions were incubated for 16 h
at 37°C. Mass analysis of the DTT-reduced mixture evi-
Fig. 2. Time-course analysis by LC-MS of refolding progression of
mCFC (A), mCFC-W107A (B), and mCFC-H104A (C). The analysis has
been performed by injecting 1 $g (wt and W107A) or 0.5 $g (H104A) of
total peptide after the indicated time intervals. Reported chromatograms
refer to traces at 215 nm and have been extracted from total PDA analysis
between 200 and 320 nm. Contextual MS analysis has been performed
obtaining molecular masses of all eluted species. Asterisks in C indicate
impurities.
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denced the presence of the expected fragments 97–110,
112–116, and 117–134, along with a number of other
higher MW peaks corresponding to partially cleaved frag-
ments. Digestion with "CHT on both domains provided,
among other peaks because of partial cleavages, the three
expected disulfide-linked peptides [EHCGSIL]-[CW],
MW 1,062.3 amu (disulfide bridge Cys99OCys117, 1–4),
[CSL]-[LPGCD], MW 822.2 amu (disulfide bridge
Cys112OCys133, 2–6), and [CR]-[HCLPQTF],MW1,119.4
amu (disulfide bridge Cys115OCys124, 3–5). In Figure
5(A–D), the base peak chromatograms (A, C) and the
corresponding extracted ion chromatograms (B, D) of
masses relative to the diagnostic peaks (see legends) are
reported. Given the similar behavior of the H104A mutant
upon refolding, we assumed that this molecule was also
fully refolded.
Fig. 3. RP-HPLC analysis of purified refolded domains mCFC (A), mCFC-W107A (B), and mCFC-H104A
(C) on a BioBasic 50# 2 mm ID column applying a 20–35% solvent B (CH3CN, 0.05% TFA) over 50 min (flow
rate 0.2 mL/min). D–F: ESI-MS spectra of purified domains obtained by infusion analysis at 5 $L/min of a 10
$g/mL solution in 0.1% HCOOH in water. Molecular masses are in very good agreement with expected
theoretical values. Molecular peaks were obtained by deconvolution of multicharge spectra using the Biomass
software implemented in the Bioworks 3.1 software package provided by ThermoElectron.
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CD Analysis
Cripto domains were studied in solution by using CD to
obtain the first structural insights and to determine their
overall tridimensional organization. CD spectra of the
three domains at neutral (7.0) and slightly acidic pH [Fig.
6(A–C)] were all dominated by broad negative bands
centered at about 200–205 nm. At neutral pH, a second
band centered at about 220 nm for the mCFC and mCFC-
H104A and at 230 nm for the mCFCW107A variant was
clearly visible. None of them showed canonical spectral
characteristics, although the curves were indicative of
well-organized structures with " and ! structure contribu-
tions. When analyzed in more acidic environments at pH
3.0, CD spectra did not change considerably from those at
Fig. 4. A: LC-MS analysis of 4-vinylpyridine-treated refolding intermediates of mCFC-W107A at 0, 60, and
240 min. The base peak chromatogram are reported. At t & 0 min, a single peak corresponding to the
hexa-alkylated polypeptide is observed (chromatogram t & 0, MW increase of 105.2 # 6 & 630.8 amu); at 60
min (chromatogram 2) all possible intermediates are present carrying 0, 2, 4, or 6 vinylpyridines. After 240 min
exposure to refolding conditions (chromatogram 3), a major product, not alkylated by vinylpyridine is eluted at
about 25.2 min, corresponding to the fully refolded domain. In (B), mass spectra taken at the indicated times
are reported.
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pH 5.0, confirming partial loss of the original structure
(not shown). CD analysis also evidenced that polypeptide
chains drastically change their conformations upon refold-
ing (not shown) and that, despite the single amino acid
substitution, remarkable structural differences exist un-
der the diverse conditions explored. Moreover, domain
structures were almost unaffected by TFE addition (not
shown), showing an outstanding conformational stability.
Binding Assays
ELISA-based binding assays to the Alk4 receptor were
performed by using immobilized Fc-fused receptor and
adding increasing amounts of soluble domains. Detection
was performed by using anti-CFC rabbit polyclonal antibod-
ies (pAb) immuno-purified from whole anti-Cripto pAb10
on Sepharose-immobilized synthetic CFC. wtCFC bound
to immobilized Alk4 in a dose-dependent manner and the
binding was saturable for concentrations higher than 450
nM, about 2 $g/mL (Fig. 7). In sharp contrast, the binding
of the corresponding W107A and H104A variants was
instead strongly reduced as compared with the wild type.
In particular, the H104A showed a residual activity of
about 40% at the highest concentration, whereas the
W107A was almost inactive.
Several experimental approaches indicate that Cripto
CFC domain is required for Cripto/Alk4 interaction and
has a pivotal role in intracellular signaling for both tumor
maintenance and progression4,5,24 and for cardiomyocyte
Fig. 5. LC-MS analysis of wild type mCFC as obtained after extensive trypsin (16 h, 1:100, w/w) and "CHT
(5 h, 1:100, w/w) digestion (base peak chromatogram) (A). In (B), the extracted ion chromatogram relative to
ions 837+ 840 amu, 1,061+ 1,064 amu, 1,118+ 1,131 amu, and 821+ 824 amu is reported. The other peaks
account for bigger fragments derived by partial cleavage. The same analysis performed on digested
mCFC-W107A (C, D). The peak at Rt 23.63 min accounts for the peptide 104–110 that bears the W107A
mutation. Disulfide-linked peptides disappeared upon analysis executed after DTT reduction.
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differentiation of stem cells. Molecularmechanisms under-
lying receptor binding and activation have been partially
elucidated by site-directed mutagenesis and involve resi-
dues located within the largest loop comprised between the
first and the second cysteine residue (Fig. 1). Further
studies of structure–activity relationship have been so far
hampered by the lack of adequate amounts of homoge-
neously refolded proteins and consequently by the lack of
structural insights about the tridimensional organization
and active conformations. To start a study on conforma-
tional properties of the CFC domain as well as to assess
the influence of single mutations on overall domain organi-
zation and receptor binding, we needed to overcome diffi-
culties associated with preparation of sufficient amounts
of structurally homogeneous molecules. To this end, we
have undertaken the chemical synthesis of mouse CFC
domain, both wild type and mutated variants. The size of
the CFC domain is far below the actual limits of stepwise
chemical synthesis: accordingly, both yields and purity
levels of crude products were relatively high, as evaluated
by RP-HPLC. Correct disulfide bridges reconstitution was
achieved by spontaneous formation and no chemical strat-
egies of selective protection/oxidation were necessary, a
fact indicative of a strong tendency of polypeptides to
adopt the correct conformation. Both wild type and mu-
tated CFC domains are indeed able to refold into native
structures by exposure to slightly oxidative conditions,
such as alkaline buffers and DMSO. This important prop-
erty, along with the capacity to bind the receptor, suggests
that CFC domains possess a structural independence and,
furthermore, indicates that refolding is probably not influ-
enced by the close vicinity of a second, highly structured
domain (i.e., the EGF-like). Binding data strongly indicate
that not only the imidazolic and indolic moieties of histi-
dine 104 and of tryptophan 107 make relevant contacts
with the receptor, but they also considerably contribute to
domain structural stability, as conformations are remark-
ably affected by substitution with alanine.
CONCLUSIONS
Herein we show, for the first time to our knowledge, that
the CFC domain of mouse Cripto, which is stabilized by
three disulfide bridges, can be conveniently prepared by
chemical synthesis, refolded by spontaneous oxidation in
diluted solutions, and purified to homogeneity by simple
RP-HPLC chromatography. The protein and its domains
are gaining a growing interest for their proven implication
in tumorigenesis and stem cell differentiation; in this
respect, the proposed chemical synthesis provides a valu-
able alternative to recombinant methods for the produc-
tion of refolded, fully active CFC domains. CFC variants,
bearing mutations on W107 and H104, can also be ob-
tained in the same way. We also show that the three
domains exhibit different kinetics of refolding and differ-
ent secondary structure, despite the single amino acid
Fig. 6. CD spectra of refolded mCFC domain at pH 5.0 and 7.0 (A).
The same spectra recorded for the W107A mutant (B) and for the H104A
mutant (C). Spectra have been acquired on 1# 10'3 M solutions using a
0.1-mm path length quartz cuvette. The domains show a progressive loss
of structure with reducing pH, reaching at pH 3.0 (not shown) complete
random conformations.
Fig. 7. Binding assays of the two synthetic domains to the recombi-
nant Alk4 (as Fc fusion protein). The assay has been performed as
described in the Methods section. Detection has been performed with
CFC affinity purified anti-Cripto polyclonal antibodies. The strong binding
capacities of wild type CFC domain are completely lost by W107
replacement with alanine, whereas a residual binding is displayed by the
H104A mutant.
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substitutions. These results represent the first step for
further studies aimed at determining, at atomic level, the
tridimensional structure of this prototypic member of a
new class of protein domains that has a potential applica-
tion as soluble receptor antagonist to block molecular
events leading to tumor progression. Finally, we have
shown that binding of CFC domain to Alk4 receptor can
occur in the absence of additional ligands and confirmed
that receptor recognition and binding by CFC involves
residues H104 and W107, as the corresponding Ala-
substituted mutants exhibit strongly reduced binding
affinities.
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For the first time fish RNases have been isolated and charac-
terized. Their functional and structural properties indicate that
they belong to the RNase A superfamily (or tetrapod RNase
superfamily), now more appropriately described as the verte-
brate RNase superfamily. Our findings suggest why previously
repeated efforts to isolate RNases from fish tissues have met
with no success; fish RNases have a very low ribonucleolytic
activity, and their genes have a low sequence identity with those
of mammalian RNases. The investigated RNases are from the
bony fish Danio rerio (or zebrafish). Their cDNAs have been
cloned and expressed, and the three recombinant proteins have
been purified to homogeneity. Their characterization has
revealed that they have indeed a very low RNA-degrading activ-
ity, when compared with that of RNase A, the superfamily pro-
totype, but comparable with that of mammalian angiogenins;
that two of themhave angiogenic activity that is inhibited by the
cytosolic RNase inhibitor. These data and a phylogenetic anal-
ysis indicate that angiogenic fish RNases are the earliest
diverging members of the vertebrate superfamily, suggesting
that ribonucleases with angiogenic activity were the ances-
tors of all ribonucleases in the superfamily. They later
evolved into both mammalian angiogenins and, through a
successful phylogenesis, RNases endowed with digestive fea-
tures or with diverse bioactivities.
One of the largest andmost studied superfamilies of proteins
is that of extracellular, pyrimidine-specific, animal RNases. It
has been labeled with different names on different bases: the
“RNase A superfamily,” a mostly historical name, recognizes
bovine pancreatic RNase A, one of the most successfully inves-
tigated proteins, as the superfamily prototype; the “pancreatic-
type RNase superfamily,” which includes not only the large
family of RNases isolated from the pancreas of many animals
but also all other RNases phylogenetically related to them; or
“the tetrapod RNase superfamily,” as to date the investigated
members of this superfamily comprise RNases frommammals,
birds, reptiles, and amphibians but not from fish (1).
Some of the tetrapod RNases have diverse bioactivities, dis-
tinct from the ribonucleolytic activity, but strictly dependent
on it, including immunosuppressive, cytotoxic, microbicidal,
and angiogenic activity (2). The RNases with angiogenic activ-
ity, the angiogenins, form a distinct family within the superfam-
ily and are identified by their ability to stimulate the growth of
blood vessels (3, 4). Angiogenins with confirmed angiogenic
activity, investigated so far only in mammals, are RNases char-
acterized by a very low catalytic activity, albeit essential to their
angiogenic activity, and the presence in their structure of only
three disulfides, compared with the four disulfide bridges of
most mammalian RNases (3–5).
Studies carried out mostly with human angiogenin (hANG)2
have indicated that hANG is recognized by a putative 170-kDa
receptor on endothelial cells (6) and is translocated to the cell
nucleus (7) where it stimulates rRNA processing (8). It should
be added that hANG and mouse angiogenins 1 and 4 also have
been found to possessmicrobicidal activity (9). Angiogenins are
fully inhibited (10) by the cytosolic RNase inhibitor (cRI), a
Leu-rich repeat protein ubiquitous inmammals (11, 12). In fact,
hANGbinds cRI with the highest affinity so farmeasured for an
RNase (Ki is lower than 1 fM), and the structure of the human
cRI!hANG complex has been studied at 2 Å resolution by x-ray
crystallography (13).
For an investigation of fish RNases we selected zebrafish
(Danio rerio), a tropical bony fish, and one of the most
favored model organism for the study of vertebrate develop-
ment including angiogenesis (14). Zebrafish has been also
proposed as an animal system for assaying angiogenesis (15,
16). Furthermore, two sequences apparently related to
RNase superfamily members are present in a zebrafish DNA
data base (Washington University Zebrafish EST Project
1998).
As fish RNases have not been investigated to date, we cloned
and expressed in Escherichia coli the cDNAs encoding three
RNase sequences from the genome of zebrafish. All three
recombinant proteins, purified to homogeneity, were active as
ribonucleases. Two of them also were found to possess angio-
genic activity. These findings, and an analysis of the phyloge-
netic relationships of the zebrafish RNases/angiogenins with
the other RNases of the superfamily, have led to the proposal
that fish angiogenins were the ancestral members of the verte-
brate RNase superfamily.* This work was supported by a PRIN (Progetti di Rilevante Interesse Nazion-
ale) grant from the Ministry of Education and University, Italy. The costs of
publication of this article were defrayed in part by the payment of page
charges. This article must therefore be hereby marked “advertisement” in
accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
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2 The abbreviations used are: hANG, human angiogenin; ZF-RNase, a ribonu-
clease from zebrafish; cRI, cytosolic RNase inhibitor; EST, expressed
sequence tag; MES, 4-morpholineethanesulfonic acid.
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EXPERIMENTAL PROCEDURES
Isolation andCloning of Zebrafish RNase cDNAs—Identifica-
tion of three genes encoding zebrafish RNases, and cloning of
their cDNAs were carried out as follows. The sequence subse-
quently labeled zf-rnase-1 was first identified in the Washing-
ton University Zebrafish EST Project 1998 data base, with
accession number wz5727.1. It contained the EST sequence
fb58b02.y1 clearly encoding a member of the pancreatic-type
superfamily, termed in the data base an “angiogenin-related
protein precursor.” A large fragment, obtained from the
Resource Center and Primary Database (RZPD GmbH, Berlin,
Germany), cloned in pSPORT1vector, was found to contain the
sequence. The N terminus of the encoded protein was identi-
fied using the SignalP 3.0 Server program. However, an inspec-
tion of the sequence in the Zebrafish genome data base, under
completion in the Sanger Institute (Cambridge, UK) revealed
that the sequence was incomplete, as it lacked the 15-nucleo-
tide stretch upstream of the cDNA stop codon that encodes the
last five amino acid residues at the C terminus of the expected
protein. Thus, two PCR steps were performed.
By a first PCR, the fragment starting with the 5!-end of the
cDNA encoding the expected RNase, devoid of the signal
peptide, was amplified. The oligonucleotides (synthesized by
MWG Biotech, Firenze, Italy) employed were: 5!-GGAATT-
CCATATGCATGTAAAGGAGCGT-3! (forward) and 5!-
CCCAAGCTTATCCGACGTTGACTTCGTCTTCATGA-
TAATGCA-3! (reverse). The reaction was performed with
the Taq polymerase High Fidelity Kit (Roche Applied Sci-
ence) following the manufacturer’s instructions. The PCR
procedure included 5min at 95 °C and 35 cycles consisting of
45 s at 95 °C, 30 s at 60 °C, 1 min at 72 °C, and 7 min at 72 °C.
The amplified fragment was isolated by low melting, 1% aga-
rose gel electrophoresis and purified using the Product Puri-
fication Kit (Roche Applied Science).
The second PCR was carried out for the addition of the
missing sequence encoding the five C-terminal amino acid
residues. The forward oligonucleotide sequence was the
same as for the previous PCR, and the reverse was: 5!-CGA-
CGTTGACTTCGTCTTCATGATAATGCACA-GGCCA-
TCCTTCC-3!. The PCR procedure and the isolation and
purification of the amplified product were as described
above for the first PCR. The amplified cDNA fragment, pre-
viously treated with restrictases NcoI and EcoRI (Novagen,
Madison, WI), was cloned into the pET22b(") expression
vector.
The gene sequence labeled zf-rnase-2 was also found in the
Washington University Zebrafish EST Project 1998 data base,
with accession number fd55b09.y1, and was recognized in the
data base as encoding a “mouse-angiogenin-related protein.” A
DNA fragment from the RZPD data base was found to contain
the sequence andwas acquired fromRZPDas cloned in plasmid
pSPORT1. The N- and C-terminal ends of the encoded protein
were identified as described above for zf-rnase-1. The cDNA of
interest (devoid of the signal peptide) was obtained by PCR
using the following oligonucleotides: forward, 5!-GTTAAGC-
CATGGATAATGAGTCCCCTTATG-3!; reverse, 5!-GAGA-
AAGAATTCTTAGCCTGAGCTGTTTACA-3!. The PCR
procedure and the isolation and purification of the cDNAwere
as described above for zf-rnase-1. The obtained cDNAwas then
treated withNdeI andHindIII restrictases and inserted into the
pET22b(") expression vector.
The third RNase-type sequence (zf-rnase-3) from zebrafish
genome was identified on the basis of its relatedness to RNase-
encoding genes in the zebrafish genome data base (accession
number ENSDARG36171) under completion in the Sanger
Institute (Cambridge,UK). Reverse transcription-PCRwas per-
formedwithmRNA fromadult (6-month) zebrafish specimens.
The oligonucleotides were: forward, 5!-TGGCCTGTGCAT-
TATCAT-3!; reverse, 5!-TTAGG-GGC-GGTTTATTTC-3!.
The PCR was carried out under the following conditions: one
cycle at 94 °C for 4 min followed by 35 cycles at 94 °C for 1 min,
50.7 °C for 2 min, 72 °C for 3 min, and finally one cycle at 72 °C
for 15 min. The amplified fragment was isolated by electro-
phoresis on a low melting, 1% agarose gel and purified as
described above. The excised band of interest was cloned in
a pGEM T-easy plasmid. The sequence encoding the signal
peptide, identified as described above for the other cDNAs,
was excised from the plasmid through a PCR with the fol-
lowing oligonucleotides: 5!-GGAATTCCATATGGAAAT-
AAGGCGCCGT-3! (forward); 5!-CCCAAGCTTAAAT-
AACACCTTTTTCATAGT-3! (reverse). The resulting
cDNA, treated with NdeI and HindIII, was cloned into the
pET22b(") expression vector.
All cloned, purifiedDNAswere certified through sequencing
(MWG Biotech) before processing. It should be noted that the
sequence of zf-rnase-3 in the zebrafish genome data base con-
tained at position 91 a guanine and at position 214 a thymine,
whereas in the sequence isolated from adult zebrafish and used
for expression of the recombinant protein, we found a cytosine
at both positions. This did not produce any change in the amino
acid encoded by the triplet 214–216 (leucine), but it altered the
amino acid encoded by the triplet 91–93 (from glycine to argi-
nine). Likely, the observed changes are due to single nucleotide
polymorphism, nonsynonymous in the latter case.
Expression and Purification of Zebrafish RNases—The three
expression plasmids, each containing a cDNA encoding a pre-
sumed zebrafish RNase, were used to transform competent
E. coli strain BL21(DE3) (provided by Invitrogen). Cells were
grown at 37 °C to an A600 # 1 and then induced with 0.1 M
isopropyl-1-thio-D-galactopyranoside and grown overnight.
Pelleted cells were sonicated at 20 kHz in an Ultrasonic sonica-
tor (Heat System Ultrasonic, Farmingdale, NY) with 30-s
impulses, each followed by a 30-s rest, for a 15-min total time.
The sonicated cells were centrifuged for 1 h at 12,000 rpm to
separate inclusion bodies. As the three proteins were found to
be expressed exclusively in inclusion bodies, these were solubi-
lized with 7 M guanidine-HCl in 100 mM Tris acetate, pH 8.4,
containing 1 mM glutathione. After flushing nitrogen for 10
min, each preparation was left for 2 h at room temperature.
Renaturation was obtained through an initial dilution 1:20,
drop by drop, in 100 mM Tris acetate, pH 8.4, containing 0.5 M
L-arginine and 1 mM oxidized glutathione.
After 24 h at room temperature, the three preparations were
dialyzed against 50 mM Tris-HCl, pH 7.4, and loaded on SP-
Sepharose columns (Amersham Biosciences) equilibrated in
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the same buffer and run on an Akta purifier (Amersham Bio-
sciences). Elution was carried out with a gradient from 0 to 1 M
NaCl in the samebuffer. In the range 0.3 of 0.4MNaCl a protein
peak was eluted, which for each preparation was found by SDS-
PAGE (17) to contain essentially a single protein with the
approximate molecular size of an RNase; a low level of RNase
activity was revealed through zymograms (see Fig. 1). These
proteins were thus labeled ZF-RNase-1, -2, and -3. The frac-
tions containing ZF-RNase-1 and -3 from the chromatographic
runs on SP-Sepharose were loaded on a reverse-phase C-4 col-
umn (Amersham Biosciences) equilibrated in 100% solution A
(composed of 5% acetonitrile (v/v) and 0.1% (v/v) trifluoroace-
tic acid). The column was eluted with a gradient in which the
concentration of solution B (composed of 90% acetonitrile con-
taining 0.1% trifluoroacetic acid) was raised to 100% in 1 h. For
each preparation a single,major protein componentwas eluted,
which by SDS-PAGE was found to contain a single protein (see
Fig. 1). As for the ZF-RNase-2 protein eluted from the
SP-Sepharose column, the corresponding fractions were
loaded on aResource-S column (AmershamBiosciences) equil-
ibrated in 50 mM Tris-HCl, pH 7.4, eluted first with a gradient
from 0 to 0.3 M NaCl in the same buffer, and then with an
isocratic run at 0.3 M NaCl. The major component eluted with
0.3 M NaCl was finally purified on a reverse-phase C-4 column,
run as described above for the final purification of ZF-RNase-1
and -3.
Assays of RNase Activity—Zymogram assays of RNase
activity were carried out as described previously (18) on 15%
SDS-polyacrylamide gels (17). Quantitative assays of RNase
activity were carried out with the fluorogenic substrate
6-carboxy-fluorescein-dArUdAdA-6-carboxy-tetramethyl-
rhodamine (Integrated DNA Technologies, Coralville, IA)
(19). The assay mixture contained 0.1 M MES, pH 6.0, 0.1 M
NaCl, 20–60 nM substrate depending on the enzyme activ-
ity, and suitable enzyme aliquots. Inhibition by cRI (Fermen-
tas International, Burlington, Ontario, Canada) of the RNase
activity of the zebrafish enzymes was measured by repeating
the assays in the presence of stoichiometric amounts of cRI.
Assays of Angiogenic Activity—The assay was based on previ-
ously described assays (20, 21) with the following modifica-
tions. A 48-well plate was coated with Matrigel (150 !l/well,
purchased from BD Biosciences) for 30 min at 37 °C. human
umbilical endothelial vein cells (3.5 $ 104 cells/well, obtained
from Cambrex, Milan, Italy) were seeded in 250 !l of EBM-2
medium (Cambrex) in the presence of hANG (a kind gift of Dr.
Guo-fu Hu, Harvard Medical School) or one of the three
zebrafish RNases at 200 ng/ml. Complete EGM-2 medium
(Cambrex) and unsupplemented EBM-2 basal medium were
used as positive and negative controls, respectively.
After 6 h of incubation, capillary-like tube formation was
examined under an inverted phasemicroscope. Cells were fixed
with phosphate-buffered saline containing 0.2% glutaralde-
hyde, 1% paraformaldehyde and photographed.
The effects of the human cytosolic RNase inhibitor on the
angiogenic activity of zebrafish RNases were analyzed by add-
ing to the medium a 5-fold molar excess of inhibitor. All assays
were performed in duplicate, and repeated three times.
Bioinformatic Tools—DNA and protein sequences were ana-
lyzed using the programs BLAST and FUGUE (22). FUGUE
utilizes environment-specific substitution tables and structure-
dependent gap penalties, so that scores for amino acid match-
ing and insertions/deletions are evaluated depending on the
local environment of each amino acid residue in a known struc-
ture. It thus produces the best possible alignment to sequences
of proteins with known three-dimensional structures, which
can be used as input formodeling. The template chosenwas the
structure of human angiogenin (Protein Data Bank code 1a4y),
and the program was MODELLER (23).
Cladistic analyses were performed by ClustalW alignments
and with the previously described program,MEGA 3.0 (Molec-
ular Evolutionary Genetics Analysis (24)). For this procedure
the neighbor-joining option was used with Poisson-corrected
distances to generate an unrooted phylogenetic tree. Phylogeny
was tested by 2000 bootstrap replications.
RESULTS
Isolation, Cloning, and Expression of Zebrafish RNases—Two
putative zebrafish RNase-type sequences were available; one of
themwas incomplete in the published data bases, in which they
were identified as proteins phylogenetically related to RNases
or angiogenins. The cDNAs encoding these putative RNases,
isolated from purchased DNA fragments, were trimmed,
reconstructed, and cloned in expression vectors. A third
RNase-type sequence was identified in the zebrafish genome,
under completion in the Sanger Institute (Cambridge, UK).
The latter was isolated through reverse transcription-PCR
with mRNA from adult zebrafish specimens. Details on the
cloning are under “Experimental Procedures.” An inspection
of the genes encoding the zebrafish RNases indicated (data
not shown) that, as for all RNase genes investigated thus far,
they are comprised in a single exon and have signal peptides
for extracellular expression.
Each cDNA was cloned in the expression vector pET22b(")
and used to transform competent E. coli strain BL21(DE3). The
proteins, expressed exclusively in inclusion bodies, were sub-
jected to denaturation/renaturation steps and purified to
homogeneity by cation exchange chromatography followed by
reverse-phase high pressure liquid chromatography as
described under “Experimental Procedures.”
Fig. 1 shows an SDS-PAGE analysis and a zymogram of the
purified proteins carried out with yeast RNA as a substrate. The
three purified proteins had ribonucleolytic activity when rela-
tively high protein aliquots (10 !g) were used. Their molecular
sizes, determined by mass spectrometry, were those expected
from their amino acid sequences (reported in parentheses follow-
ing). They were: 14,323.91 % 0.48 Da (14,330.44); 14,455.49 %
0.27 Da (14,461.42); and 14,464.78 % 0.49 Da (14,471.41) for
ZF-RNase-1, -2 and -3, respectively. These findings also indi-
cated that the six Cys residues in each sequence form three
disulfide bridges, as there is a difference of 6 Da between the
observed and the theoretical mass values. Furthermore, amino
acid sequencing carried out for theN-terminal 25 residues indi-
cated that the three proteins had the expected N-terminal
sequences.
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An examination of these sequences revealed that the catalyt-
ically essential residues of RNase A, namely His-12, His-119,
and Lys-41, were present at correspondingly close sequence
positions in all three proteins (see Fig. 2). Furthermore, all three
proteins had the standard “RNase signature,” i.e. CKXXNTF,
whereas the other RNase signature, namely PVHXD/E, was
present in ZF-RNase-2 but was only partially conserved in ZF-
RNase-1 and -3, as it occurs in several sequences of non-mam-
malian RNases.
The overall sequence identity values of the three proteins
with respect to RNase A were: 31.3, 33.3, and 30.8%, for ZF-
RNase-1, -2, and -3, respectively. Higher identity values could
be calculated for the three proteins with respect to human
angiogenin, anRNasewith angiogenic activity. The latter values
were: 35.4, 36.2, and 36.2 for ZF-RNase-1, -2, and -3, respec-
tively. In particular, all three proteins shared with all mamma-
lian angiogenins thus far analyzed a consensus sequence within
the first 12 N-terminal residues characterized as “YXX-
FLXQH.” All three ZF-RNases possess three disulfides (see
above) as has been found for non-mammalian RNases and
mammalian angiogenins as well.
Characterization of Zebrafish RNases—The purified proteins
were tested for RNase activity with a sensitive assay (19). This
led to the evaluation of the low activity of these enzymes and
provided a direct determination of kcat/Km values. As tabulated
in Table 1, the three zebrafish proteins have a very low RNase
activity with respect to that of RNase A, but it is comparable
with that of human angiogenin.
When we tested the three RNases in the presence of cRI, the
human cytosolic RNase inhibitor, we found that under the con-
ditions of the assay stoichiometric amounts of cRI fully inhib-
ited (100%) the RNase activity of ZF-RNase-1 and -2, whereas
ZF-RNase-3 was inhibited only by 23%.
The finding of a very low RNase activity of the zebrafish
enzymes, typical of angiogenins and the sequence similarities
reported above between the zebrafish RNases and mammalian
angiogenins motivated us to determine whether the zebrafish
enzymes possess angiogenic activity. The assays were based on
the formation of capillary-like microtubules when primary
endothelial cells were grown onMatrigel in the presence of the
effectors (20, 21). Fig. 3 shows that ZF-RNase-1 and -2 were
found to possess amarked angiogenic activity, comparablewith
that of human angiogenin. ZF-RNase-3, instead, was found to
have no angiogenic activity. Interestingly, the angiogenic activ-
ity of ZF-RNase-1 and -2 was completely inhibited by the cyto-
solic RNase inhibitor (see Fig. 3).
These findings led us to analyze the structure of the zebrafish
RNases through modeling based on the structure of human
angiogenin (Protein Data Bank code 1a4y) as a template. The
FIGURE 1. SDS-PAGE and zymogram of recombinant zebrafish RNases.
Upper and lower panels: lane 1, ZF-RNase-1; lane 2, ZF-RNase-2; lane 3, ZF-
RNase-3. Upper panel: lane 4, standard protein markers. Lower panel: lane 4,
RNase A; lane 5, human angiogenin.
FIGURE 2. Amino acid sequences of zebrafish RNases. To allow compari-
sons, the sequences of bovine pancreatic RNase A and human angiogenin
(ANG_HUMAN) are also shown. In the expressed sequences of zebrafish
RNases, the signal sequences of the ribonucleases were replaced by methio-
nine codons. Residues shared by all three zebrafish RNases and residues
shared also by either RNase A or hANG or both are shown with a dark back-
ground. The putative RNase and angiogenin sequence “signatures” (see
“Experimental Procedures”) are marked with asterisks. At position 32 of ZF-
RNase-3 there is an Arg residue, as encoded by a cgc triplet in the cDNA
employed for expression (see “Experimental Procedures”), whereas in the
sequence from the zebrafish genome data base under completion in the
Sanger Institute (Cambridge, UK), a ggc triplet is present at that position,
encoding a Gly residue.
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modelswere validated usingANOLEA (25), and the occurrence
of dihedral " and # angles outside allowed areas of the Ram-
achandran plot was assessed with SEGNO (26).
As expected from the sequence-structure alignments of the
sequences as produced by FUGUE (see Fig. 2), the models con-
structed for Zf-RNase1, -2, and -3 (shown in Fig. 4) closely
resemble the structure of angiogenin, with two significant dif-
ferences: the loop between the first and second $-helix is
shorter in zebrafish RNases; and the loop that follows the sec-
ond $-helix in the sequence was found to be longer in the
zebrafish proteins (see Figs. 2 and 4).
ZF-RNases in the RNase Vertebrate Superfamily—A prelim-
inary phylogenetic analysis of zebrafish RNases was carried out
by comparing their amino acid sequences with those available
in the vertebrate RNase superfamily. The rootless tree illus-
trated in Fig. 5, with radiant branches, includes representative
members from the main classes of vertebrate RNases. The
bootstrap values are satisfactory, allowing inspection of the
relationships among clades with low or no ambiguity. Only for
the divergences, bird/mammal and fish/amphibian bootstrap
values lower than 50% were found (42 and 46%, respectively).
The monophyletic group of fish RNases, including the three
zebrafish RNases and a sequence identified in salmon (NCBI
accession number BG936674), appears to be closely related to
the family that comprises non-mammalian RNases from
amphibians, reptiles, and birds.Mammalian pancreatic RNases
(RNases 1) are quite distant from fish and other non-mamma-
lianRNases. The independent clade ofmammalian angiogenins
(RNases 5) is instead more closely related to the early diverged
non-mammalian RNases than to mammalian pancreatic
RNases 1. It should be noted that ZF-RNase-3, which has been
found devoid of angiogenic activity, appears to be more closely
related to salmon RNase than to the other two ZF-RNases
endowed with angiogenic activity.
DISCUSSION
We report here the first investigation on RNases from fish.
AsRNases thus far have been found and studied in all tetrapods,
the characterization of three fish proteins as RNA-degrading
enzymes leads to a more appropriate definition of the animal,
extracellular, pyrimidine-specific RNase superfamily as the ver-
tebrate RNase superfamily.
Based on the inspection of RNase genes, it has been proposed
(27) that the earliest members of the RNase superfamily are
related to the families of RNases 5 (angiogenins) and/or non-
mammalian RNases. The findings reported here on the charac-
terization of three fish RNases provide experimental support to
this hypothesis. Moreover, based on the evidence that indeed
two fish RNases, namely ZF-RNase-1 and -2 from zebrafish, are
FIGURE 3. Angiogenic activity of ZF-RNase-1 and -2. Assays were carried
outwith primary humanumbilical endothelial vein cells. Positive (A) and neg-
ative (B) controls were obtained by using complete EGM-2medium and non-
supplemented EBM-2 medium, respectively. C, assay for human angiogenin.
D and E, positive results obtained with ZF-RNase-1 and -2. F, negative result
with ZF-RNase-3. G and H, respectively, show the effects of the cytosolic
RNase inhibitor on the angiogenic activity of ZF-RNase-1 and -2.
FIGURE 4. Structural models of zebrafish RNases. ZF-RNase-1, ZF-RNase-2,
and ZF-RNase-3 are shown in cyan, gray, and blue, respectively. The structure
of human angiogenin (Protein Data Bank code 1a4y) is shown in red. The N-
and C-terminal ends are marked. The extended loop in region 36–44 (ZF-
RNases numbering) is shown.
TABLE 1
Ribonuclease activity of zebrafish RNases compared with the
activities of RNase A and hANG
Enzyme kcat/Km
M&1 s&1
RNase A 1.6% 0.12$ 107
Zf-RNase-1 2.3% 0.25$ 103
Zf-RNase-2 6.3% 0.50$ 102
Zf-RNase-3 6.0% 0.74$ 103
hANG 7.4% 0.72$ 102
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endowed with angiogenic activity, we propose that all verte-
brate RNases evolved from early diverged angiogenic RNases
from fish. Upon evolution, they diversified and experienced
selection, thus engendering two distinct evolutionary major
clades: (i) that of pancreatic RNases possessing digestive abili-
ties, or diverse noncatalytic bioactions, that were still based on
their ability to degrade RNA (2); (ii) that of mammalian angio-
genins, with angiogenic activity and a low but essential RNase
activity (4).
In fact, as one of the three investigated zebrafish RNases,
ZF- RNase-3, does not have angiogenic activity, we can suggest
that RNases with or without angiogenic activity diverged at a
very early stage in the evolution of fish, before the divergence of
the closely related amphibian RNases. However, early diverged
fish RNases have all the features of superfamily members: they
are encoded in a single exon, possess a signal peptide, are sta-
bilized by disulfides, and are endowed with ribonucleolytic
activity determined by the presence of two critically positioned
His residues and a Lys residue.Work is in progress on the iden-
tification of RNases fromhagfish, lampreys, and elasmobranchs
(dogfish) to verify whether the RNase/angiogenin scaffold pre-
ceded the divergence of bony fishes. It should be noted that
RNase superfamily members have not been found in inverte-
brates (28). It would be interesting to verify whether the fish
angiogenins investigated here have anymicrobicidal activity, as
has been found for human and some mouse angiogenins (9).
A comparison of the two
zebrafish RNases with angiogenic
activity, ZF-RNase-1 and -2, with
the best characterized mammalian
angiogenins shows that similarities,
but also differences, are detectable.
As found for mammalian angio-
genins (7), the zebrafish angiogenic
ZF-RNase-2 contains in its se-
quence a putative nuclear transloca-
tion signal at positions 30–36
(KRKITAK). A string of basic amino
acids is also present in ZF-RNase-3
(RRITR at positions 30–34), but ZF-
RNase-3 does not display angio-
genic activity. The fish angiogenins
do not present in their primary
structures the two Asn residues (at
sequence positions 61 and 109 of
human angiogenin) inwhich deami-
dation leads to a loss of angiogenic
activity (4). It has been presumed
that mouse Ang-4 is devoid of
angiogenic activity because it pre-
sents a replacement of Asn with Lys
at position 61 (3); however,
ZF-RNase-1 and -2 do not present
this critical residue, yet they have
angiogenic activity. It should be
noted that the angiogenic activity of
human and other mammalian
angiogenins were assayed with a
chicken experimental system (29), whereas fish angiogenins
were assayed with a human system (see “Experimental Proce-
dures”). Tests carried out on mammalian and fish angiogenins
with identical assay systems should help to verify the actual
significance of sequence signals in the tested angiogenins.
The availability of the angiogenins described here can help to
investigate angiogenesis in zebrafish and the role(s) of the
newly isolated angiogenins in the angiogenic process, both in
the adult animals and in developing zebrafish embryos. In fact
angiogenesis has been successfully studied in zebrafish as a very
convenient experimental system (14), and developing zebrafish
embryos have been proposed as a model for angiogenic/anti-
angiogenic drug screening (15).
It is surprising that the human cytosolic RNase inhibitor can
exert its inhibitory effects on fish RNases. The presence of cRI
has been reported only in mammals (11, 12, 30). Furthermore,
cRI has been found to inhibit all tested mammalian RNases,
with the exception of seminal RNase, a finding explained by the
dimeric structure of this RNase, which is the only RNase of the
superfamily with such a structure (31). It does not inhibit an
amphibian RNase such as onconase (32), whereas RNase inhib-
itors from birds and amphibians do not inhibit RNase A, the
superfamily prototype (30). Thus, either fishes possess an
RNase inhibitor homologous to mammalian cRI that has not
yet been detected in evolutionarily related species, or we have a
FIGURE 5. Rootless phylogenetic tree of the vertebrate RNase superfamily. The tree shows the close rela-
tionship of fish RNases with mammalian angiogenins on one hand and non-mammalian RNases on the other.
Mammalian pancreatic (and seminal) RNases 1 appear to be more distant. ZF-RNase-3, devoid of angiogenic
activity, is more closely related to salmon RNase than to the other ZF-RNase-1 and -2. The neighbor-joining
method was used with Poisson-corrected distances.
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case of proteins that just happen to interact apart from any
basic biological significance, as in the case of biotin and avidin.
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